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Executive Summary 
Diabetic foot ulcerations (DFUs) remain a severe complication of Diabetes 
Mellitus (DM) and the most critical risk factor for lower limb amputations. Their 
management involves a dynamic approach which includes wound debridement, 
antibiotics to treat infections, mechanical off-loading, as well as foot care 
education. However, the overall wound management of chronic DFUs can 
undergo extended periods without any healing response due to multiple complex 
pathophysiological mechanisms which are involved in patients who have 
diabetes. Despite all the challenges faced with managing or treating DFUs, 
several clinical trials suggest Low-Level Laser Therapy (LLLT), more recently 
termed Photobiomodulation (PBM), as an alternative promising treatment 
modality. Photobiomodulation has shown potential in improving the healing rate 
of chronic diabetic ulcerations when combined with other conventional 
treatments. However, until this study, there have been no studies, in South Africa, 
that have investigated the effects of Blue laser therapy in the management of 
DFUs and whether skin tone has a positive or negative impact in these patients. 
This study used a prospective experimental design with a single-blinded control. 
The aim was to investigate the effect of phototherapy (Blue light) in treating Type 
II diabetic ulcerations in different skin tones (Fitzpatrick skin Type III and Type V). 
The study had a sample of 19 participants with 22 lower limb ulcers fitting the 
inclusion criteria. These ulcers were randomly divided into the control (n=9) and 
experimental groups (n=13) with Skin Type III and V. Participants in the 
experimental group received treatment with PBM, where wound bed and wound 
edges were irradiated locally with 625 nm and 850nm (1200 mW output) for ~ 1 
minutes, delivered twice a week for 12 weeks. Photographic images were 
recorded every week for both the control and experimental group to analyse the 
healing progress. The experimental group participants completed a pain intensity 
questionnaire after each treatment, to analyse the adverse effects of PBM. 
Of the 22 ulcers, 68.2% were on male participants, and this was the same 
percentage for the Fitzpatrick Skin Type V. At week one, 59.1% ulcers presented 
as Wagner’s Grade 1 ulcer compared to 40.9% that presented as Grade 2 ulcers 
in both groups.  
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The mean duration of this ulcers was 8.04 months, with most ulcers between 1-
5 months duration in both groups [63.6% (n=14)]. Significant changes, in ulcer 
parameters and areas, were observed in both groups, over the period of 12 
weeks. In the control group, 25% of ulcers showed complete healing or wound 
closure [p = 0.043], compared to 58.3% of ulcers in the Photobiomodulation 
(PBM) group by week 12 [p = 0.028]. All healed ulcers in the PBM group were in 
the Fitzpatrick Skin Type V participants. This can be due to the concentration of 
melanin and thus chromophores in the epidermis of these participants and their 
properties of absorbing light. The action of low-level laser therapy is based and 
dependent on the absorption of the light by tissues, which will generate 
modifications in cell metabolism and promote tissue regeneration.  
Results of the Pain Intensity Questionnaire indicated that during and after 
irradiation mild to moderate pain, heat, erythema, pricking, and tingling 
sensations were experienced in this group. However, at the end of treatment (12 
weeks), only 10% of the participants reported mild to moderate heat, pricking, 
and tingling sensations. None of the participants reported pain at the end of this 
study. 
In conclusion, PBM improved the healing rate of chronic diabetic foot ulcers when 
used in combination with podiatric interventions. The findings suggest that PBM 
might reduce the frequency and chances of lower limb amputation, without any 
adverse effects on the darker skin tones.  It has been proven that irradiating with 
a 200 mW, 810 nm laser induce three to six times more heat in dark skin than in 
the other skin tone groups. However, in this study 625 nm and 850nm (1200 mW 
output) applied for ~ 60 seconds, did not induce any severe thermal effect in the 
darker skin tone participants. These effects are however a function of wavelength, 
power, and pulse duration. Time exposure is a crucial point because the duration 
of exposure depends on the penetration depth and the type of diseases treated 
(DFUs). The findings of this study can therefore be used as a guideline to 
practically use PBM for DFUs in darker skin. 
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CHAPTER 1: BACKGROUND  
1.1 Introduction  
Chronic diabetic foot ulcers are one of the common ulcers seen in hospital wound 
clinics and podiatry clinics. In both settings, these ulcers still prove challenging to 
manage and show delayed response to standard wound treatments.  
1.2 Background 
Diabetic foot ulcerations are a severe complication of DM and the most critical 
risk factor for lower limb amputations. Diabetes is a chronic hyperglycemic 
condition related to the resistance of target cells to the action of insulin; leads to 
degenerative disorders caused by macroangiopathy, microangiopathy and 
neuropathy (Edmonds, 2010; Minatel et al., 2009). All of these factors favour the 
occurrence of lower limb ulcers and delay their healing (Clarke, 2010; Minatel et 
al, 2009). These ulcers are a significant cause of hospital admissions for people 
with diabetes in the developed world and constitute considerable morbidity 
associated with diabetes, often leading to pain, suffering, and overall poor quality 
of life for the patient (Brem & Tomic-Canic, 2007). It is therefore clear that there 
is a need and important to introduce new treatment modalities for DFUs to 
improve the healing rate and outcome of diabetic ulcerations.  
Despite all these challenges, there is an increasing cause for optimism in the 
treatment of diabetic ulcers. More research is being conducted to enhance 
understanding and correction of pathogenic factors of these ulcers, and it is giving 
new hope to the problem of impaired healing of diabetic ulcers. However, this is 
still ongoing and very limited in South Africa. More research still needs to be 
executed to establish the best treatment modality taking in consideration the 
differences in skin tones.  
In vitro studies conducted by the University of Johannesburg Laser Research 
Center (Houreld & Abrahamse, 2007 & 2010), suggest that PBM positively 
stimulate wounded diabetic ulcer fibroblasts resulting in increased viability, 
proliferation, Adenosine Triphosphate (ATP), growth factors, cytokines and nitric 
oxide as well as a decrease in cellular damage and proinflammatory cytokines; 
all of which are important in wound healing. In this way, PBM induces cellular 
changes which are believed to accelerate tissue repair and relieve pain in vivo. A 
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further suggestion is that blue light has bactericidal effects compared to red light 
alone. Therefore this could suggest that a combination of the red and blue light 
laser can be used to treat chronic infected ulcers. The previous in vitro study 
findings motivated and led to this research project. Thus, actual (in vivo) diabetic 
foot ulcers were irradiated by blue light (625nm and 850nm) to either dispute or 
support these suggestions/results. 
1.3 Problem Statement 
Since the early ‘90s, researchers have been investigating phototherapy or PBM 
as a treatment modality. It has been found to improve the healing rate for chronic 
ulcers abroad/overseas significantly.  
Despite the published literature, phototherapy is still not an accepted and 
established treatment modality for chronic DFUs. There is also little knowledge 
and scientific research on the use of PBM, red or blue light, on diabetic foot ulcers 
affecting patients with type II diabetes in South Africa. Additionally, there is a lack 
of data both in South Africa and abroad on the effects of PBM on skin colour when 
treating ulcers.  
1.4 Aim and Objectives 
This study aimed to determine if chronic lower limb ulcers in patients with type II 
diabetes respond better to the combined treatment of podiatric intervention and 
phototherapy (625 nm and 850 nm / 1200 mW output).  
The following objectives were identified in order to realise the aim of the study,  
 To compare standard podiatric treatment alone with combined therapy 
of podiatric treatment and phototherapy, 
 To determine the rate of healing of diabetic foot ulcers, 
 To determine whether phototherapy  is affected by skin tone/colour 
when treating ulcers, 
 To assess if any pain is experienced by participants after treatment. 
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1.5 Possible benefits 
The possible benefits of this study would be to identify a new treatment modality 
that would improve on current treatment strategies.  Conventional Podiatric 
interventions have showed limited to significant success in treating diabetic 
ulcers.  Photobiomodulation (PBM) has also shown significant effects that 
improve wound healing.  After completion of this study, a combined therapeutic 
approach used by Podiatrists may be identified which would improve the 
outcomes of diabetic patients suffering from ulcers in their lower limbs.   
In addition, much research has been done to determine the benefits of PBM on 
wounds worldwide.  However, the participants of most of these studies have light 
skin in the Fitzpatrick scale of 1-3.  This study may shed light on the effect of PBM 
on darker skin types and elucidate the possible need to change the laser 
parameters needed for more effective treatment. In the long term, the findings of 
this study may have an impact on the quality of life of patients with chronic 
diabetic foot ulceration. Moreover, the preliminary findings of this study might lead 
to more extensive clinical trials on the use of PBM in DFUs. Such clinical trials 
might allow for the subsequent acceptance of PBM as part of mainstream 
management of DFUs across all levels of care in South Africa.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Diabetes mellitus (DM) 
The prevalence of DM as a common metabolic disease is increasing worldwide. 
Approximately 50% of diabetes cases are undiagnosed, with the majority of these 
occurring in low-income and middle-income countries. In Africa, the proportion of 
undiagnosed diabetes is 69.2% (Pheiffer et al, 2018). The prevalence of Type II 
diabetes mellitus (T2DM) in Africa has increased over the past decades, with 
South Africa rated as moderate, and high in adults aged 20 – 79 years (Clarke, 
2010; Dunbar, Hellenberg and Levitt, 2015). The International Diabetes 
Federation estimated that in 2017, 451 million adults worldwide had diabetes, 
with projections of 693 million cases by 2045 (IDF Diabetic Atlas, 2017).  
In 2014, 22 million people with diabetes were living in Africa, and 2.713 million of 
them were South Africans (IDF Diabetic Atlas, 2014). In South Africa, the 
prevalence of diabetes mellitus is about 15.8% in the Indian population, 3.5% in 
the White population and 4.8% – 6% in the Black population (Seedat, 2006). In 
2012, a study in Cape Town found a rising prevalence of diabetes of 7-11.7% in 
urban-dwelling, adult black South Africans between 1990 and 2008/2009 (Peer 
et al. 2012). The current prevalence of T2DM in SA is 5.5%, likely an 
underestimation, but predicted to rise in the future (IDF Diabetic Atlas, 2017). 
The most severe and costly complication of DM worldwide is foot complications 
leading to ulceration preceding amputations (Clarke, 2010; Clayton & Elasy, 
2009; Dunbar et al, 2015). Data on DFUs in South Africa remain very sparse. 
However, just as in other parts of the world, DFUs are associated with a high risk 
of amputation.  Studies report that DM accounted for 60.2% of the non-traumatic 
lower extremity amputations in public hospitals in the Cape Town Metropole, 
South Africa (Clarke & Tsubane, 2008; Clarke, 2010; Dunbar et al, 2015). 
2.2 The diabetic foot 
Diabetic foot ulcers and amputations can reduce the patient’s level of function 
and independence and as such, may place a burden on the individual, family, 
and health care system. Patients’ may view amputations as an end to productive 
living and a start to long-term disability and loss of independence.   
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Diabetic foot is a classification used to describe the foot in a diabetic patient that 
is at risk of developing or already has ulceration. It is also associated with 
neuropathy and peripheral arterial disease of the lower limb in a patient with 
diabetes (Alexiadou & Doupis, 2012). Diabetic foot is said to be more prevalent 
in Type 2 diabetic patients than in Type 1 diabetic patients, as most people with 
Type 2 diabetes may live several years with the condition, not being aware of 
their condition before being diagnosed (IDF, 2017; WHO, 2017). There are three 
entities of the diabetic foot: the neuropathic foot, the neuroischaemic foot and 
ischaemic foot.  
Neuropathic foot present with the loss of protective sensory mechanisms but 
have good circulation, whereas neuroischaemic foot present with absent foot 
pulses accompanied by neuropathy. Ischaemic foot present with no circulation 
but might have adequate sensation (Edmonds, 2010; Alexiadou & Doupis, 2012). 
Ischaemia, an inadequate blood supply to the feet, is the most destructive 
complications of diabetes. It predisposes a patient to ulcerations, as well as 
gangrene, which may result in lower limb amputations (Nteleki & Houreld, 2012). 
Whether single or in combination, these entities lead to alterations in foot shape, 
thus allowing increased pressure points and make the skin susceptible to damage 
from footwear with an increased potential for ulceration and delayed healing 
(Clarke, 2010).  
The pathway to diabetic foot ulceration is complex and involves an interaction of 
many factors. Whereas none of the factors discussed in this literature review will 
alone result in ulceration, it is the interface and amalgamation of risk factors 
working together that leads to skin breakdown and subsequent DFUs as outlined 
in Figure 1. 
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Figure 1. Physiological and Physical Pathways contributing to the development 
of diabetic foot ulceration (Boulton AJM, 2016).  
2.3 Diabetic foot ulcers 
Diabetes is the most common cause of foot ulcers. About 25% of patients with 
diabetes mellitus are likely to develop ulcers during their lifetime (Chadwick et al, 
2013).  Peripheral neuropathy is a significant contributor to diabetic foot ulceration 
and is frequently the most common microvascular complication of diabetes 
mellitus (Bergin et al., 2012; Chadwick et al., 2013; Edmonds, 2010; Nteleki & 
Houreld, 2012). Most diabetic lower limb ulcers occur in the presence of 
peripheral neuropathy, foot deformity and trauma. Peripheral vascular disease 
and infection are believed to be the complicating factors that prevent or delay 
ulcer healing (Bergin et al., 2012). 
2.3.1 Classification of DFUs 
Diabetic foot ulcers can result from multiple factors, and their classification is 
according to the relative contribution of late diabetic complications of peripheral 
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neuropathy and vascular diseases, similar to the diabetic foot classification 
above. They are also classified according to their severity or in grades using the 
universally accepted validated tools such as the Wagner and University of Texas 
classifications (Ho et al., 2012). Wagner’s classification grades 0–V, divide ulcers 
from superficial or deep ulcers with or without the presence of osteomyelitis or 
gangrene (Wagner, 1981). The University of Texas classification (stages 1–5) 
further assess any presence of infection and ischaemia (Cavanagh et al., 2005; 
Ho et al., 2012).  
These classification systems help provide prognosis on healing and aid in the 
formulation of management plans. However, patients and clinicians must 
understand that increasing stage, regardless of grade, is associated with 
increased risk of amputation and prolonged ulcer healing time (Ho et al., 2012). 
Additionally, deep ulcers of long duration have a prolonged healing time (Parisi 
et al., 2008). The reason for delayed healing is because the deep ulcers penetrate 
through the dermis, leading to more tissue damage, increased chances of 
necrosis, and osteomyelitis if neglected. The treatment in such cases is then 
more likely to be minor or major amputations (Musa & Ahmed, 2012). A study by 
Edo et al. (2013) support this reasoning. In his study, he found that 45.9% of their 
participants presented with Wagner grade IV and V ulcers, had an amputation 
rate of 52.5%.  
2.3.2 Risk factors for Diabetic Foot Ulcers and Delayed Healing 
DFUs can result from multiple factors; furthermore, these factors can also lead to 
impaired wound healing for diabetic patients. These factors can be either external 
factors or internal/intrinsic factors (Petrova & Edmonds, 2006).  External factors 
include repeated trauma to the foot due to peripheral neuropathy, arterial 
insufficiency and foot deformities that result in abnormal pressure distribution 
(Petrova & Edmonds, 2006; Guo & DiPietro, 2010). Intrinsic factors include 
hypoxia, deficiency of growth factors, changes in extracellular matrix components 
with excess proteases, reduced fibroblast activity, cellular abnormalities, and 
deficiencies of angiogenesis, nitric oxide abnormalities (Petrova and 
Edmonds,2006).  
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Many other factors have been suggested, in literature, to contribute to the 
development of DFUs and their delayed healing. Factors such as poorly 
controlled hyperglycaemia, duration of diabetes, improper footwear, callus, 
history of previous ulcers/amputations, older age, impaired vision, chronic renal 
disease and poor nutrition have been demonstrated to play a role in the 
pathogenesis and progression of diabetic foot ulceration (Kavitha et al., 2014).  
In a study by Shahi et al (2012), to determine the prevalence of and risk factors 
for foot ulceration in diabetic cases of North India, it was found that essential risk 
factors for DFUs included age >50 years, duration of diabetes: 4 to 8 years and 
> 8 years, rural location, oral hypoglycaemic treatment, insulin treatment, and 
tobacco use. Ahmad et al (2017) also found similar results in a study; in their 
study, they further identified that lack of awareness, male sex and barefoot 
walking as other major risk factors of developing of diabetic foot ulcers. 
Edo et al. (2013) found that spontaneous blisters from ill-fitting footwear are one 
of the common risk factors of DFUs in a study to determine the risk factors, ulcer 
grade, and management outcome of patients with diabetic foot ulcers managed 
in a tropical tertiary hospital in Nigeria. Their study also found that poor diabetes 
control does not only play a role in delaying wound healing and providing an 
environment for infection to thrive, but mortality can result from diabetic 
ketoacidosis in the poorly controlled patients (Edo et al., 2013). Though this can 
be of short-term, health care practitioner must be familiar with its signs & 
symptoms and management. Deribe et al. (2014) reported similar results in a 
study conducted in Ethiopia. In addition to their findings, they reported that rural 
residence; the presence of co-morbidity such as obesity, duration of diabetes, 
mean arterial blood pressure and occupation (farmworkers) are factors 
associated with a diabetic foot ulcer.  
The leading common risk factor of DFUs based on literature is peripheral 
neuropathy. Similarly, the main etiological factors associated with peripheral 
neuropathy are poor glycaemic control, visceral obesity, diabetes duration and 
height, with possible roles for hypertension, age, smoking, hypoinsulinemia, and 
dyslipidaemia (Ziegler, 2008). It is then evident that to prevent DFU development 
and delayed healing; treatment strategies must deal with peripheral neuropathy. 
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That approach will require identifying the underlying causative factor/s and 
treating or controlling them. Peripheral neuropathy in diabetic patients results 
from a complex interplay with multiple interactions between metabolic and 
vascular factors (Ziegler, 2008): 
1. Increased flux through the polyol pathway that leads to the accumulation 
of sorbitol and fructose, myo-inositol depletion, and reduction in Na+, K+ -
ATPase activity. 
2. Nerve membrane structure and microvascular and hemorrheologic 
abnormalities as a result of disturbances in n-6 essential fatty acid and 
prostaglandin metabolism. 
3. Endoneural microvascular deficits with subsequent ischemia and hypoxia, 
generation of reactive oxygen species (oxidative stress), activation of the 
redox-sensitive transcription factor NF-kB, and increased activity of protein 
kinase C (PKC).  
4. Deficits in neurotrophism, leading to reduced expression and depletion of 
neurotrophic factors such as nerve growth factor (NGF), neurotrophin-3, 
and insulin-like growth factor and alterations in axonal transport. 
5. Accumulation of non-enzymatic advanced glycation end products (AGEs) 
on the nerve and/or vessel proteins. 
6. Immunological processes with autoantibodies to the vagal nerve, 
sympathetic ganglia, and adrenal medulla as well as inflammatory 
changes. 
In the foot with the loss of the protective sensation (painless feet), motor 
dysfunction, and reduced sweat production due to autonomic involvement result 
in a markedly increased risk of callus and foot ulcers. Since this is a major 
contributory factor for diabetic foot ulcers and the lower limb amputation rates in 
diabetic patients, early detection by screening is of paramount importance 
(Ziegler, 2008). However, late presentation or delayed referral of these patients 
can result in this complication missed and thus worsening the outcome of DFU 
management (Edo et al., 2013). 
Although literature have identified all these factors associated with DFUs and 
ways to manage them, the fact remains that there is a shortage of trained 
Diabetes care specialists and or Podiatrists in South African Primary Health Care 
sector. Moreover, most patients seek treatment from health care providers who 
have little or no training in managing diabetes and its complications such as 
diabetic foot ulcers. 
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2.3.3 Diabetic foot ulceration management 
Management of diabetic foot requires a holistic approach which involves a 
focused interdisciplinary team that includes a wound nurse, a podiatrist and other 
allied health professionals (Bergin et al, 2012; Chadwick et al, 2013; Clarke & 
Tsubane, 2008; Clarke, 2010; Kim et al, 2012; Nteleki & Houreld, 2012; Houreld, 
2014). This team is trained to implement and provide local wound care as the 
general standard of wound management in wound-care clinics. Local wound care 
involves debridement of necrotic tissue and callus, cleansing with suitable 
solutions, wound dressing, and prescription of topical or oral antibiotics when 
infection is present, revascularization and offloading (Bergin et al, 2012; 
Chadwick et al, 2013; Clarke & Tsubane, 2008; Clayton & Elasy, 2009; Kim et al, 
2012).  
However, this can last for extended periods without any healing response, due to 
the multiple complex pathophysiological mechanisms such as hypoxia, 
dysfunction in the fibroblasts and epidermal cells, impaired angiogenesis and 
neovascularisation, high levels of metalloproteases, damage from oxygen 
radicals and advanced glycation end-products; seen in diabetic patients. These 
factors receive relatively little or no attention at all (Petrova & Edmonds, 2006; 
Guo & DiPietro, 2010). It is then evident that management for diabetic ulcers 
should focus on two main areas. These are external factors that cause diabetic 
foot ulcers and the internal factors that lead to impairment of wound healing. Such 
an approach indicates that there is a need to look beyond dressings and 
offloading but to focus more at the cellular level of the wound healing process.  
Research has shown that understanding and correction of these pathogenic 
factors, combined with stricter adherence to standards of care and technological 
breakthroughs, is giving new hope to the problem of impaired healing of diabetic 
ulcers (Falanga, 2005). However, it might not always be possible because the 
multidisciplinary team is not always complete, and these technological 
breakthroughs are either not available or approved, especially in South Africa. 
2.4 Podiatric management 
Podiatrists approach diabetic ulcerations in a context of the overall structure and 
function of the lower limb. They perform local wound care and offloading with limb 
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function in mind, and therefore, continuous podiatric management can prevent 
ulcer recurrence through offloading strategies and diabetic foot education (Kim et 
al, 2012).  
2.4.1 Wound debridement  
Wound debridement is the removal of non-viable/unhealthy tissue that if not 
removed, it might promote infection and delay healing. There are different 
methods of debridement used in diabetic ulceration management, including sharp 
surgical debridement, non-surgical sharp debridement, autolytic and enzymatic 
debridement (Chadwick et al, 2014; Strohal et al, 2013). Wound debridement is 
an essential tool in the management of diabetic ulcerations as it allows a 
comprehensive examination of the ulcer bed and assessment of the actual ulcer 
size. It also has a potential to convert a chronic ulcer to an acute ulcer, aid in 
removing colonising bacteria in the ulcer and it also reduces local pressure on 
the ulcer (Chadwick et al, 2014; Strohal et al, 2013; Chadwick et al, 2013; Clayton 
& Elasy, 2009).  
Some literature advises that the patient’s vascular status must always be 
determined before sharp debridement as it could create a larger non-healing ulcer 
in vascular compromised patients (Brown, 2013; Bergin et al., 2012; Chadwick et 
al., 2014). Chronic neuropathic DFUs may accumulate callus and slough with 
excess exudate, which encourages the formation of biofilm (bacterial 
colonisation), promoting the risk of infection and thus delay healing (Williams et 
al., 2005; Wolcott et al., 2009). Sharp debridement helps to break down these 
bacterial colonies, thus reducing the bacterial load within an ulcer even in the 
absence of overt infection, and so promotes the release of growth factors to aid 
the healing process. Also, this offers an opportunity for additional antibiotic 
interventions, applied topically or systemically, to be useful as it temporarily 
disrupts biofilm defence colonies and forcing microbes to become more 
susceptible to these interventional treatments as well as the host’s immune 
defence (Wolcott et al., 2009).   
Literature suggests that frequent debridement of DFUs and chronic venous leg 
ulcers increase wound healing rates and closure of the ulcer when combined with 
other conventional and advanced therapies (Cardinal et al., 2009). Wilcox and 
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colleagues investigated the frequency of debridement and the time to heal for 
different types of ulcers, including DFUs and chronic venous ulcers (Wilcox et al., 
2013). They found that the median time to heal after weekly or more frequent 
debridement for DFU was 21 days, compared to 64 days when debridement 
frequency was in the range of every one to two weeks, and 76 days when 
debridement was once every two weeks or more (Wilcox et al., 2013).  
Another study by Ahmad and colleagues, which assessed the efficacy of radical 
debridement and skin grafting in treating DFUs, compared with other 
conservative wound treatments (such as the use of dressings, negative-pressure 
wound therapy and hyperbaric oxygen), the results showed a 100% skin graft 
take in 80% of the patients on day four after surgery. In their study, wound 
debridement was done three times a week (Ahmad et al., 2012). Both studies 
support that frequent debridement of chronic DFUs, promote healing and speed 
up the healing process of these ulcers. In the current study, debridement was 
performed twice a week, as participants in both groups were seen twice a week 
for treatment. 
2.4.2 Offloading  
Offloading is also an essential tool in the healing of diabetic foot ulceration, 
particularly in the case of plantar neuropathic ulcer, or for secondary prevention 
in patients with healed ulceration but have a foot deformity (Bergin et al., 2012; 
Clayton & Elasy, 2009).  The main goal of offloading is to redistribute pressures 
evenly around the ulceration sites and pressure points at risk of increased 
pressure bearing (Chadwick et al., 2013). Several offloading techniques are used 
by Podiatrists, in South Africa and overseas. These include felt padding, 
prescription orthotics and insoles, removable cast walkers and total contact 
casting (Bergin et al., 2012; Clarke & Tsubane, 2008; Kim et al, 2012).  
The use of suitable or proper footwear combined with custom-made orthotic 
devices is considered the primary means of protecting the foot from excessive 
plantar pressure during walking, thus reducing the incidence of ulceration. A study 
by Mueller et al. (2006), which investigated the effect of total-contact cast inserts 
(TCIs) and metatarsal pads (MPs) on metatarsal peak pressures and pressure–
time integrals support this approach. That study found that the TCI and MP 
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caused a substantial and additive reduction in pressure (29 to 47%) under the 
metatarsal heads on the feet by increasing the contact area of weight-bearing 
forces when compared to wearing shoes alone (Mueller et al., 2006).  
Tong and Ng (2010) investigated the amount of pressure reduction that occurred 
in feet when using different types of padding and four insole materials commonly 
used in podiatry. In their study, they found that all four commonly used materials, 
Slow Recovery Poron (SRP), Poron, Poron + Plastazote firm (PPF) and Poron + 
Plastazote soft (PPS) could reduce pressure across the whole foot. The PPF 
achieved the most significant result of 29% pressure reduction. Additionally, they 
combined PPF with a semi-compressed felt metatarsal pad with an aperture on 
the first metatarsophalangeal joint of both feet. The peak pressure in this area 
showed a significant reduction of 37% compared to a 29% decrease with PPF 
alone (Tong & Ng, 2010).  
It is important to note that pressure responses vary in the two studies, suggesting 
that pressure reduction in terms of using footwear and orthotic devices is highly 
dependent upon the condition of the patient’s feet and the material used. It is 
unclear how this factor is considered by podiatrists, nurses and other healthcare 
professionals when treating DFUs. 
Over the years, total-contact casting (TCC) has been known to be more effective 
in the treatment of non-infected diabetic plantar neuropathic ulcers, compared to 
other removable off-loading devices mentioned above (Sambrook et al., 2015). 
However, TCC is a time-consuming and challenging treatment for podiatrists to 
apply, and generally, there is low patient tolerance, with several side effects 
associated with its application. Therefore most clinicians, including podiatrists, 
prefer not to use this technique and instead prescribe various other off-loading 
techniques that are far easier to apply (Raspovic and Landorf, 2014). These can 
be the other alternative non-removable devices or removable devices like instant 
total contact cast or removable cast walkers/moon boot (RCW) (Armstrong et al., 
2005; Faglia et al., 2010). 
Studies show that whether the off-loading device is removable or non-removable, 
it can be used effectively to redistribute pressure on the plantar aspect of the foot. 
However, results are dependent on the patient’s compliance with wearing the 
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devices, especially the removable devices regularly. A comparative study on the 
efficacy RCW and a non-removable fibreglass off-bearing cast (TCC) by Faglia 
et al. (2010) in DFU healing over a 90-day period , found that 73.9% of patients 
in the TCC group and 72.7% in the RCW group achieved complete healing (Faglia 
et al., 2010).  
Before Faglia et al., Armstrong and colleagues in 2005 performed a study to 
evaluate the effectiveness of an RCW and an ‘instant’ total-contact cast (iTCC) 
over 12 weeks in neuropathic DFUs. They reported significant ulcer healing rates 
of 82.6% in the TTC group and 51.9% in RCW group. The advantage of using 
RCW is that it can be easily applied and removed. However, its ease of 
application is also its shortfall in that patient adherence to the walker is a 
significant factor in non-healing ulcers and frequent recurrence in those who do 
not continually wear their RCWs (Boghossian et al, 2017). To avoid this, all 
involved in the management of DFUs should employ a variety of skills. Training 
workshops on how to apply instant total contact cast for neuropathic DFUs could 
also be of benefit; as patients can benefit from the forced compliance of the iTCC 
while enjoying the more tolerable offloading capability of this device.  
2.4.3 Wound dressing 
Both offloading and debridement are considered very important to the healing 
process of diabetic lower limb ulcers. However, selecting the right wound dressing 
is also essential and the characteristics of specific dressing type can be 
beneficial; depending on characteristics of the individual ulcer (Bergin et al, 2012; 
Chadwick et al, 2013; Clarke & Tsubane, 2008; Clayton & Elasy, 2009). There 
are various wound dressings available for the management of diabetic foot ulcers 
including hydrogels, hydrocolloids, alginates, foam, silver-impregnated 
dressings, growth factors, and silicon impregnated atraumatic dressings, and 
more (Kavitha et al, 2014).  
To promote wound healing, the wound dressing must comprise of these 
characteristics: it must be sterile, not contaminate the wound with foreign 
particles, maintain a moist wound healing environment, absorb excess exudate, 
non-adherent & non-toxic, protect the wound from microorganisms, allow 
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gaseous exchange and control wound odour, and provide thermal insulation and 
mechanical protection (BNF, 2010; Kavitha et al, 2014). 
Most diabetic foot ulcers produce copious amount of exudate and the primary 
dressing, therefore, should be either foam-based or Hydrofiber, both which will 
absorb the exudate (Speak, 2014; Kavitha et al, 2014). Diabetic foot ulcers are 
often colonised with microorganisms (biofilm) first before they become infected 
(Cavanagh et al, 2005; Kavitha et al, 2014); therefore choosing an appropriate 
dressing to address and prevent infection is essential to achieve effective 
treatment of these ulcers. Silver impregnated dressings are believed to be 
antibacterial (Wall, 2010) and thus useful in the treatment of DFUs.  However, 
some literature states that there is a need for more research to establish whether 
silver-containing dressings clear wound infection (Storm-Versloot et al., 2010).  
Podiatrists are very well trained and well equipped to assess and implement these 
treatment modalities in the management of diabetic lower limb ulceration (Kim et 
al, 2012). However, these treatment modalities can go on for a long time with 
slow or no healing response of an ulcer, and this has a negative influence on a 
patient’s quality of life. Thus, there is a need for new DFUs treatment modalities 
to be generated or introduced, such as phototherapy, to help improve the healing 
rate and outcomes of diabetic ulcerations. 
2.5 Phototherapy  
Phototherapy is a therapeutic modality that involves the use of laser light, at a 
specific wavelength at low intensities, stimulate biological processes in tissues 
(Nteleki & Houreld, 2012; Houreld, 2014). Low-level laser therapy (PBM) is widely 
used to accelerate tissue repair in surgery, dentistry, dermatology, somatology, 
pain management and ulcer healing (Hamblin & Demidova, 2006). Unlike the 
high-intensity medical lasers used to cut and coagulate tissues, PBM involves the 
use of medical lasers that operate at intensities too low to damage tissue or cause 
a rapid and significant increase in tissue temperature (Dyson, 2014). 
2.5.1 Mechanism of action 
Photobiomodulation is understood to supply direct biostimulative light energy to 
body cells; however; its full mechanism of action is not known (Beckmann et al, 
2014). For PBM to be effective, the targeted tissue must absorb the light (Dyson, 
16 
 
2014; Hamblin & Demidova, 2006). Photo acceptors or chromophores within the 
cell absorb photon energy. The primary photo acceptors are thought to be the 
cytochrome c oxidase inside the mitochondrion, and the absorption of photons 
increases the amount of energy-rich adenosine triphosphate (ATP) produced by 
the mitochondria which also temporally increase cell membrane permeability to 
calcium ions, acting as a stimulus for cell activity (Nteleki & Houreld, 2012). In 
this way, when absorbed, the photons induce cellular changes, which accelerate 
tissue repair and relieve pain (Dyson, 2014). Figure 2 illustrates the mechanism 
of action of PBM. 
Figure 2. Mechanism of Action of PBM at cellular level.  Light energy is absorbed 
by chromophores, which convert light energy into chemical energy that activates 
a cascade of cellular and molecular pathways contributing to wound healing 
(Amid et al, 2014) 
2.6 Low-Level Laser Therapy accelerates wound healing in vitro studies. 
According to literature, phototherapy stimulates mitochondrial oxidative 
metabolism in vitro, and increase cell and tissue repair in vivo (Nteleki & Houreld, 
2012). In vitro experimentations with cultured human keratinocytes, mast cells, 
lymphocytes, endothelial cells and fibroblasts indicated potential effects of PBM 
in the treatment of chronic ulceration. Human skin fibroblasts are one of the 
targets in phototherapy as they are highly involved in initiating the healing process 
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by producing cytokines and undergoing proliferation, migration, deposition, and 
remodelling of extracellular matrix to form granulation tissue (Houreld & 
Abrahamse, 2010). Figure 3 illustrates the effects of PBM on wound healing. 
 
Figure 3. Photobiomodulation and its cellular cascade effects that promote 
accelerated wound healing (Martin R, 2011).  
At the correct laser parameters, PBM has been shown to positively stimulate  
diabetic ulcer fibroblasts (Nteleki and Houreld, 2012) resulting in increased 
viability, proliferation, ATP, growth factors, cytokines and nitric oxide as well as a 
decrease in cellular damage and proinflammatory cytokines (Houreld & 
Abrahamse, 2010; Beckmann et al, 2014; Houreld, 2014). Studies done on 
wounds suggest that fibroblasts transform into myofibroblasts, which develop in 
the granulation tissue to produce wound contraction (Hamblin & Demidova, 2006; 
Dyson, 2014). A study by Minatel et al. (2009), found that the healing effect of 
combined 660 nm and 890 nm light resulted in rapid granulation and healing rate 
in a treatment group than in the placebo group; correlating the cellular effects 
produced by phototherapy.  
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Samaneh et al. (2015), review paper, reported that visible light at a wavelength 
of 630-780 nm could penetrate to a depth of 0.5-50 mm. This wavelength has 
shown great potential for wound healing. They also suggested that applying laser 
at doses between 4 J/cm2 and 8 J/cm2 are more effective (Samaneh et al, 2015).  
Houreld and Abrahamse (2007 & 2010) conducted a study to test the positive 
effects of low-intensity laser irradiation of different wavelengths on cellular 
migration, viability and proliferation in diabetic wounded and healthy human skin 
fibroblasts. Their findings showed that diabetic wounded cells irradiated at 1.064 
nm had a lesser degree of migration, viability, and proliferation. Whereas cells 
irradiated at 632.8 nm had a higher degree of haptotaxis, migration and ATP 
luminescence compared to cells irradiated at 830 nm (Houreld and Abrahamse 
2007 & 2010). 
2.7 The Effect of PBM on infection 
As previously stated, different wavelengths of light are used for different 
applications in phototherapy as they have different depths of penetration into 
human tissue. Visible red, Infra-red and near infra-red have been demonstrated 
to penetrate deep tissues and are absorbed by cytochrome c. oxidase compared 
to violet and blue spectrum lasers. Flavins (flavoproteins) and porphyrins lacking 
transition metal coordinating absorb blue laser (Nteleki & Houreld, 2012; 
Beckmann et al, 2014). Blue light absorption by these molecules has been shown 
to have bactericidal effects compared to red light. After absorption by these 
molecules, a photochemical reaction occurs and forms reactive free radicals that 
lead to bacterial destruction (Dyson, 2014; Hamblin & Demidova, 2006).  
Several studies have found that, at different wavelengths, the blue light laser is 
bactericidal to different infectious organisms such as methicillin-resistant 
Staphylococcus aureus (MRSA), Propionibacterium acne and Pseudomonas 
aeruginosa. Enwemeka et al. found that blue light (470 nm) was able to kill MRSA 
in vitro. Lipovsky et al. suggested that high-intensity visible light in the range of 
400-1000 nm was bactericidal to S. aureus, P. aeruginosa and Escherichia coli, 
to name a few. Ankri et al. suggested irradiation at a wavelength of 408 nm for 
treating infected wounds to clear the infection, followed by irradiation at 730 nm 
to speed up the healing process (cited in Houreld, 2014). 
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Red lasers as well as blue laser improve perfusion by the release of nitric oxide 
(NO) from nitrosyl complexes with haemoglobin, enhanced epithelialization, and 
elevated keratin-10 mRNA level (Beckmann et al, 2014). Studies have shown 
that NO inhibits the activity of cytochrome c oxidase, and this was initially seen 
off as an imperfection (Hamblin, 2006). However, there is evidence that blue light 
facilitates the recovery of mitochondria inhibited by NO gas. The release of NO 
from mitochondrial complexes leads to an improved wound healing via the NO 
pathway induced endothelial cell migration which activates growth factors 
resulting in an increase keratin expression (Beckmann et al, 2014). The ability of 
the blue laser to improve perfusion by the release of nitric oxide is significant and 
shows that a combination of red light laser and blue light laser can be used to 
treat infected ulcers. Thus, the current study used blue laser light to treat diabetic 
ulcer to promote both healing and apparent superficial infection. 
2.8 Possible advantages of combining PBM and Podiatric intervention 
Wound debridement in ulcers is a vital stage in the healing of chronic like DFUs 
as it returns the wound into acute inflammation (Halim et al, 2012). Mechanical 
or sharp debridement is one of the essential parts of wound treatment protocols 
in podiatry (Clarke & Tsubane, 2008; Kim et al, 2012). It helps facilitate the wound 
healing process by converting chronic inflammation to acute inflammation (Halim 
et al, 2012). Thus, phototherapy can be used immediately after debridement to 
stimulate proliferation of endothelial cells and fibroblasts, accelerating the 
development of granulation tissue over which epidermal cells migrate to achieve 
wound contraction (Dyson, 2014). 
Sharp debridement temporarily, disrupts the biofilm defence colonies, forcing 
microbes to become more susceptible to interventional treatments (Wolcott et al., 
2009). Ideally, following sharp debridement blue light laser must be used to 
irradiate DFUs as it bactericidal against different infectious organisms. The blue 
light laser is active and can eradicate microbes such as methicillin-resistant 
Staphylococcus aureus (MRSA), S aureus, Escherichia coli, Propionibacterium 
acne and Pseudomonas aeruginosa, which is critical in the treatment and clearing 
of infection. In turn, this can speed up the healing process of ulcers (Houreld, 
2014).  
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Since peripheral neuropathy is the major contributor to DFUs and is known to 
results from a complex interplay with multiple interactions between metabolic and 
vascular factors seen in diabetic patients (Ziegler, 2008); perhaps PBM can assist 
in controlling or reversing it. According to literature, PBM promotes nerve 
regeneration by stimulating the production of nitric oxide that relaxes endothelial 
cells, which form the lining of blood vessels and thus, improves blood flow. It also 
stimulates mitochondrial ATP production, accelerates antioxidant mechanisms, 
and improve cell function; resulting in all of these processes serving to repair 
damaged nerve endings (Robinson et al., 2017). Further studies and 
investigations are ongoing in this area to validate the efficacy of this intervention.  
In addition, most DFUs occur in the presence of peripheral neuropathy, foot 
deformity and trauma, due to uneven distribution of pressure in a diabetic foot 
(Bergin et al., 2012). To redistribute pressures evenly, around the ulceration sites 
and other risk pressure points to a broader contact area is achieved by offloading 
techniques (Chadwick et al., 2013). It is then somehow clear that combining PBM 
with podiatric interventions might further improve and accelerate wound healing 
as both these interventions play a role in controlling or eliminating both the 
internal and external risk factors of DFUs. Therefore, the current study aimed to 
determine and establish if combining these two interventions can accelerate 
wound healing in Type II Diabetic patient with Fitzpatrick Skin Type III and V. 
2.9 Fitzpatrick skin types 
South Africa has diverse ethnic groups with different skin colours and might have 
more sunlight compared to other regions of the world. In 1975, Fitzpatrick 
developed a skin typing system based on the history of an individual’s tendency 
to get burns or tan from ultraviolet radiation (UVR). There are six classifications 
from this system: skin type I, II, III also known as white-skinned. Skin type IV is 
for light brown, type V for dark brown skin and type IV for black skin. Fitzpatrick 
classification of skin type has been used to estimate the risk of skin cancer and 
cutaneous malignant melanoma (Ravnbak, 2010). Melanin and other molecules 
absorb ultraviolet radiation which can cause structural cell damage. Its effects 
are, however, wavelength-dependent, just like laser irradiation.  
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Melanin is the skin pigmentation produced from melanocytes in the epidermis, 
and it plays a role in photo-protection of the skin. The UV radiation may have 
some beneficial effects on humans, but most evidence suggests that it is toxic to 
human skin and health. The acute adverse effects of UV radiation are erythema, 
keratitis and immunosuppression (Ravnbak, 2010). According to literature 
investigating the effects of phototherapy in wound management, PBM is an 
adverse effect free treatment modality in the management of ulcers. However, 
the uses of phototherapy in dermatology clinic have proven to have unwanted 
side effects, especially in dark skin toned patients.  
Most of these effects relate to melanin’s vast absorption spectrum of light (250-
1200 nm). Visible ultraviolet and infrared light can target melanin. In darker skin 
types (type IV to VI), epidermal melanin competes as significant chromophores 
and laser light intended for deep tissue might not reach them; reducing its 
efficacy. Unwanted thermal injuries such as blistering, transient or permanent 
dyspigmentation, textural change and scarring can occur due to the conversion 
of the absorbed light within the pigmented epidermis to heat (Battle & Hobbs, 
2003; Battle & Soden, 2009). However, this might not be obvious in people of 
skin type II or III in their natural untanned state (Battle & Soden, 2009). The 
current study investigated the effects of skin tone/colour with the application of 
PBM in DFU treatment.  
2.10 Conclusion 
Literature suggests that PBM is one of the treatment modalities that, when 
combined with other conventional treatments, has shown potential in assisting 
and improving the healing rate of chronic diabetic ulcerations. Therefore, this 
study aimed to determine if chronic lower limb ulcers in patients with Type II 
Diabetes respond better to the combined treatment of podiatric intervention and 
phototherapy and whether there are any adverse effects when treating these 
ulcers in patients with skin type III and V.  
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CHAPTER 3: METHODOLOGY AND RESEARCH DESIGN 
3.1 Research design 
To realize the aim and objectives of the study, the researcher chose a prospective 
experimental single-blinded controlled design for this study (Appendix A). 
A prospective study is a study that watches for outcomes, such as the 
development of a disease (in the context of the current study the efficacy of PBM 
in DFUs healing rate), during the study period and relates this to other factors 
such as suspected risks (Elmes, Kantowitz & Roediger III, 2011; Jhangiani, 
Chiang & Price, 2015). The study was also an experimental design study. An 
experimental design is a study designed accurately to answer the question of 
whether there is a causal relationship between two variables. This design was 
suitable since experiments have high internal validity because of the way they 
are conducted with the manipulation of the independent variable and the control 
of extraneous variables, which provides strong support for causal conclusions 
(Jhangiani, Chiang & Price, 2015).  
3.2 Materials and methods 
3.2.1 Setting  
The setting for this study was the University of Johannesburg Podiatry clinic and 
Helen Joseph Hospital: Podiatry Department and Surgical Outpatient 
Department. These settings were suitable for examination and management of 
diabetic ulcerations under appropriate sterility as diabetic ulcers are highly prone 
to secondary complication such as infection. 
3.2.2 Sample and population 
In this study, the population were all Type II Diabetic patients presenting with a 
diabetic lower limb ulcer at UJ Podiatry clinic and Helen Joseph Hospital.  
3.2.3 Study sample and sampling methods 
The researcher used non-probability purposive sampling techniques to select 
participants in this study. Purposive sampling is a judgmental and deliberate 
selection of study participants for inclusion in the study (Grove, Burns & Gray, 
2013). The sample was the 19 diabetic patients who volunteered to participate in 
the study, who had 22 lower limb ulcers among them.  
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3.2.4 Inclusion criteria   
 Type II diabetes with neuropathic or mixed ulcers 
 Lower extremity ulcer 
 A stable or worsening ulcer which has been present for a minimum of four 
weeks 
 Fitzpatrick skin type III and V  
 Willingness to participate in and commitment to the study 
 Signed consent to participate in the study. 
3.2.5 Exclusion criteria  
 Evidence of acute cellulitis, osteomyelitis or gangrene anywhere in the 
affected extremity 
 Presence of one or more conditions (a renal, hepatic, hematologic, 
neurologic or immune disease) not related to diabetes 
 Presence of malignant disease (other than basal cell carcinoma) not in 
remission for more than five years 
 Use of oral or parenteral corticosteroids, immunosuppressive or cytotoxic 
agents 
 Known infection with HIV or the presence of AIDS 
 Use of other investigational drugs or devices within 30 days of recruitment 
into the study 
 Other leg ulcers, such as ulcers due to decubiti or vasculitis 
The researcher randomly divided the participants who met the prerequisite 
inclusion criteria of the study into four groups:  
 Group 1 was the control group of Fitzpatrick skin type III, receiving placebo 
irradiation and standard podiatry treatment for diabetic ulcers. 
 Group 2 Fitzpatrick skin type III received irradiation of the ulcer and 
standard podiatry treatment for diabetic ulcers. 
 Group 3 was the control group for Fitzpatrick skin type V, receiving placebo 
irradiation and standard podiatry treatment for diabetic ulcers. 
 Group 4 Fitzpatrick skin type V received irradiation of the ulcer and 
standard podiatry treatment for diabetic ulcers. 
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3.3 Ethical consideration 
To ensure patients’ rights to equality, justice, human dignity/life and protection 
against harm, the researcher observed ethics throughout this study. Ethics are a 
set of moral principles that are widely accepted, which guide the researcher in 
observing ethical and moral rules. Research participants were therefore, treated 
with respect and dignity during the collection of data. The researcher protected 
the rights of respondents in this study and took every precaution to prevent any 
violation of their ethical rights. The following ethical principles guided this study: 
permission to conduct research, informed consent, anonymity and privacy, 
confidentiality as well as autonomy. 
3.3.1 Permission to conduct the study. 
 
The University of Johannesburg’s Faculty of Health Sciences Higher Degrees 
and Research Ethics Committee (Appendix A and Appendix B) approved the 
study and issued an ethical clearance. Upon receipt of ethical clearance, the 
podiatry clinic manager and Helen Joseph Hospital Ethics Committee (Appendix 
C) were approached to request access to diabetic patients.  
3.3.2 Informed consent 
Informed consent means that participants should understand that they are taking 
part in research and what it requires of them. Thus, it is an agreement by a 
prospective subject to participate voluntarily in a study after he or she has 
assimilated essential information about the study (Grove, Burns & Gray, 2013). 
In this study, the researcher provided details on the PBM intervention to all 
potential participants.  
Potential participants were alerted of their right to choose either to volunteer for 
the study or not as well as their right to withdraw at any point during the study 
without prejudice. Potential participants were at liberty to discuss their 
participation in this study with their treating clinicians. Diabetic patients presenting 
with diabetic foot ulcers were approached to solicit their participation in the study. 
The researcher read an information letter (Annexure D) outlining the aim, 
objectives as well as risks and benefits of the study to all potential participants. 
The researcher also dealt with any specific question that potential participants 
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raised. Patients who elected to participate signed a consent form (Annexure E) 
to indicate their informed consent before any data collection.  
3.3.3 Right to Confidentiality 
Confidentiality in a participant’s information is the management of private data in 
research in such a way that only the researcher knows the subjects’ identities 
and can link them with their responses (Grove, Burns & Gray, 2013). Only the 
researcher and research had access to the data collected as part of this study. 
The researcher kept all hard data in a lockable cabinet and soft data in a 
password-protected file. The Department of Podiatry will keep data collected in 
this study, for three years. Furthermore, the researcher will ensure participant 
confidentiality in all subsequent publication of the current study findings in peer-
reviewed journals. 
3.3.4 Anonymity and privacy 
Anonymity and privacy is freedom to determine the time, extent, and general 
circumstances under, which private information to share with or withhold from 
others (Grove, Burns & Gray, 2013). In this study, the researcher did not collect 
any patient identifying data as part of data collection. Thus, safeguarding 
participant anonymity and privacy (Pera & van Tonder, 2011). 
3.3.5 Right to self-determination or autonomy  
Autonomy is when a person is capable of controlling his or her self-destiny and 
have the freedom to conduct his or her life without force or control (Pera & van 
Tonder, 2011). Thus, participants in this freely choose whether to participate or 
not without any external control, force or exploitation as well as had an option to 
withdraw from the research at any time during data collection.  
As the study involved a clinical intervention, the researcher emphasised to each 
participant their right to withdraw without any changes to their usual treatment. 
Additionally, the researcher informed each participant that there had been no 
risks reported with PBM in wound management, as it is a non-invasive therapy. 
Moreover, potential participants were informed that any adverse effects occurring 
during this study would be dealt with efficiently, and after completion of the study, 
participants will continue receiving their long term treatments. 
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3.4 Study procedure 
After signing the informed consent, each participant had to complete the study 
questionnaire (Appendix F). The questionnaire explicitly designed for this study 
was to ensure that the participants met all the prerequisites inclusion criteria of 
the study. The researcher evaluated the vascular status and sensation of each 
participant as part of patient assessment. The Wagner ulcer grading system was 
used to assess, measure and graded each ulcer as follow: 
 Grade 1: Superficial diabetic ulcer 
 Grade 2: Deep ulcer; involving the tendon, ligament, joint capsule or 
fascia 
 Grade 3: Deep ulcer with abscess or osteomyelitis 
 Grade 4: Gangrene affecting the portion of the forefoot 
 Grade 5: Extensive gangrene of the foot 
This study included only participants with Grade 1 and Grade 2 ulcers of at least 
four weeks’ duration.  
3.4.1 Podiatric treatments 
All participants received their routine general podiatric treatment for diabetic 
ulcers, which included wound debridement (sharp debridement), cleansing with 
saline and dressing with a silver dressing (Biatain Silicone Ag). Antibiotics and 
offloading devices were prescribed when needed. The common offloading 
devices prescribed were moon-boots and custom-made simple insoles, 
depending on the site of the ulcer and deformity present. Diabetic foot care 
education also formed part of these participants’ management.  
The researcher took baseline images for each presenting ulcer before treatment, 
and then again at each treatment session. A camera (Nikon D7000, 18-55mm 
lens) set at a fixed height of ~ 80 cm using a tripod and at a distance of 30 cm 
from the ulcer to ensure standard photography. Participants were treated twice a 
week until the ulcer was healed or for a maximum of 12 weeks.  
3.4.2 Phototherapy 
All participants in the study (PBM) group wore the required safety goggles, which 
filtered out the laser light. Participants were treated with the 
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Photizo®Physio/Home642 unit (Photon Therapy Systems (Pty) Ltd, Kosmosdal, 
Samrand, South Africa) with a 1200 mW cluster probe twice a week before wound 
dressing was completed (Figure 4). The cluster probe has eleven (625nm and 
850nm) LEDs emitting blue light (at 1200 mW output) for ~60 seconds. The 
instrument is pre-programmed and to treat ulcers, the “Wounds” protocol was 
chosen. The probe was covered with clear, sterile plastic to prevent cross-
contamination. The covered probe was lightly pressed onto the ulcer (contact 
mode) and sequentially one spot at a time was treated until the entire ulcer was 
treated. This delivered a total energy of 3 J/cm2 per spot (15 cm2) with a 
penetration depth of ~ 12 mm (60% dose absorbed in superficial tissue and 40% 
penetrates further.   
 
Figure 4. Photizo®Physio/Home642 unit. 
 
Post irradiation, ulcers were dressed according to the standard podiatric 
treatment. This depended on the wound and the stage of healing (e.g. moist / dry 
wound, infection/no infection.). Participants were treated twice a week until the 
ulcer healed for a maximum of 12 weeks. Although no pain from irradiation  was 
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expected, participants were requested to complete a pain questionnaire 
(Appendix G)  on a weekly basis. 
3.5 Data analysis 
The researcher measured the size of the ulcer and area of granulation tissue 
using Image J® software. The following quantitative data were analysed using 
SPSS version 25.  Basic comparative statistical analysis was undertaken to 
determine the healing rate in different skin Types III and V. The results are 
presented in tables, bar charts, line graphs and ulcer images in the next chapter. 
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CHAPTER 4: RESULTS 
4.1 Introduction  
The initial target sample was 50 ulcers (25 in PBM and 25 in Control). However, 
the researcher could not reach this number due to the high participant attrition 
rate. This study used new intervention in the treatment of DFUs.  
Despite the lower than expected number of ulcers treated using the PBM method, 
the findings of the study are significant. As alluded in the methodology section, 
this study was an experimental design study. The purpose of an experimental 
design is to demonstrate that two variables are statistically related and to show 
that in such a way that supports the conclusion that the independent variable 
(PBM irradiation) caused the observed difference in the dependent variable 
(DFUs).  
The findings of the study showed marked improvement and statistically significant 
ulcer healing (p-value control 0.043 vs p-value PBM 0.028). Therefore, though 
limited in the number of participants, this study provides preliminary results on 
the effectiveness of PBM in vivo.  
4.2 Demographics  
The demographics in this study include the following: gender, ulcer classification, 
ulcer duration, and duration of DM, comorbidities/risk factors and the skin tone of 
each participant. The study sample comprised of 19 participants, 12 males and 7 
females, with 22 lower limb ulcers. Out of all the 22 ulcers, 15 ulcers (68.2%) 
were from male participants, and seven ulcers (31.8%) were from females. Table 
1 shows the distribution of ulcers in the different genders. 
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Table 1. Ulcer-Gender distribution of participants in this study. 
 
The ulcers were randomly divided into Control group (n=9) and PBM group 
(n=13). Table 2 shows, the classification of ulcers, according to Wagner’s 
classification, and it shows that 59.1% were Grade 1 ulcers vs 40.9% Grade 2 
ulcers in both groups.  
Table 2 Diabetic foot ulcer Classification/grade. 
Group Grade 1 Grade 2 Total  
Control  7 (77.8%) 2 (22.2%) 9 (100%) 
PBM  6 (46.2%) 7 (53.8%) 13 (100%) 
Total  13 (59.1%) 9 (40.9%) 22 (100%) 
 
A majority of ulcers duration was between 1-5 months in both the Control and 
PBM group, respectively (Figure 5). The mean duration of ulcers was 8.05 
months, with a minimum duration of one month and maximum duration of 24 
months. 
 Group Gender 
Male Female 
Control Count 6 3 
%   66.7% 33.3% 
PBM Count 9 4 
%   69.2% 30.8% 
Total Count 15 7 
% 68.2% 31.8% 
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Figure 5. Ulcer duration in Control and PBM groups indicating majority of ulcers 
duration ranged between 1-5 months.  
The mean age for the two groups was 54.36, with a minimum age of 44 and a 
maximum of 74 years. Table 3 presents the descriptive statistics of age 
distribution in the two different groups.  
Table 3.  Age Distribution of the study groups. 
Group 
 
Statistic 
Control Mean 57.00 
95% Confidence 
Interval for Mean 
Lower Bound 50.42 
Upper Bound 63.58 
5% Trimmed Mean 56.78 
Median 56.00 
Variance 73.250 
Std. Deviation 8.559 
Minimum 44 
Maximum 74 
PBM  Mean 52.54 
95% Confidence 
Interval for Mean 
Lower Bound 48.92 
Upper Bound 56.16 
5% Trimmed Mean 52.49 
Median 52.00 
Variance 35.936 
Std. Deviation 5.995 
Minimum 44 
Maximum 62 
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The study groups were divided according to their skin tone (Fitzpatrick Skin Type 
III and V) and the results are presented in Table 4. 
Table 4 Fitzpatrick Skin Type III and V Distribution. 
 Group Skin Type Total 
III V 
Control Count 3 6 9 
%  33.3% 66.7% 100.0% 
PBM Count 4 9 13 
% 30.8% 69.2% 100.0% 
Total Count 7  15  22  
% 31.8% 68.2% 100.0% 
 
The results in Figures 6 shows the duration of Diabetes Mellitus (DM) for both 
groups. The mean duration of DM was 11.6 years with a minimum of two years 
and a maximum of 27 years.  
 
Figure 6. Duration of Diabetes distribution indicates a majority of the participants’ 
DM duration, in the PBM group (n=9), ranged between six years and >20 years.  
The results in Table 5 show the summary of the other risk factors (co-morbidities) 
that have an impact on wound healing. Out of 22 ulcers, 81,8% were on 
participants diagnosed with Hypertension and 45.5 % had DM >10-year duration 
in both groups, respectively. 
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Table 5 Risk Factors for Diabetic Ulcers. 
 Group Risk factors Total 
Male 
sex 
DM duration 
>10 yrs. 
Peripheral 
Neuropathy 
Hypertension  Smoking  
Control Count 6 3 4 9 5 9 
% 66.7 33.3 44.4 100 55.6% 100% 
PBM Count 9 7 9 9 7 13 
% 69.2% 53.8% 69.2% 69.2% 53.8% 100% 
Total Count 15 10 13 18 12 22 
% 68.2% 45.5% 59.1% 81.8% 54.5% 100% 
 
4.3 Ulcer healing rate  
Overall ulcer healing rate results showed complete healing in 25% (n=2) in the 
Control group compared to 58.3% (n=7) in the PBM group (Figure 7).  
 
Figure 7. Overall Control versus PBM healing indicates 25% (n=2) of ulcers in 
the control group were healed completely compared to 58.3% (n=7) in the PBM 
group. A majority of ulcers (n=5) in the control group remained a same Grade 
(Not improved) at the end of this study compared to the PBM group (n=1). 
The results in Table 6 show how the ulcers severity (Grade) in both groups 
changed at the end of the study. These results show that 42.9% of Grade 2 ulcers 
and 80% of Grade 1 ulcers were completely healed in the PBM group. 
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Table 6 Ulcer severity (grade) before and after treatment in both groups.  
Group  Grade after Total 
Healed ulcer 
area 
Grade 1 Grade 2 
Control Grade 
before 
Grade 
1 
Count 2 4 0 6 
% 33.3% 66.7% 0.0% 100.0% 
Grade 
2 
Count 0 1 1 2 
%  0.0% 50.0% 50.0% 100.0% 
Total Count 2 5 1 8 
%  25.0% 62.5% 12.5% 100.0% 
PBM Grade 
before  
Grade 
1 
Count 4 1 0 5 
%  80.0% 20.0% 0.0% 100.0% 
Grade 
2 
Count 3 4 0 7 
% 42.9% 57.1% 0.0% 100.0% 
Total Count 7 5 0 12 
% 58.3% 41.7% 0.0% 100.0% 
 
Both groups showed significant changes in the ulcer perimeters and areas over 
the study period (Figures 8 and 9). 
Figure 8 Means of Perimeters for the 12 weeks of treatment indicate significant 
changes for both groups respectively. The marginal means of parameters of the 
Week  
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control group were higher (>140 mm) than that of the PBM (<100 mm), but these 
were significantly reduced overtime.  
The findings showed statistically significant reduction (p=0.011 Control group vs 
p=0.003 PBM group) in ulcer perimeters between week 1 and week 4 (Table 8). 
Table 7 Statistical significant changes in Ulcer Perimeters. 
Group Week1 
Perimeter 
– Week4 
Perimeter 
Week1 
Perimeter 
– Week8 
Perimeter 
Week1 
Perimeter 
- Week12 
Perimeter 
Week4 
Perimeter 
– Week8 
Perimeter 
Week4 
Perimeter 
– Week12 
Perimeter 
Week8 
Perimeter 
– Week12 
Perimeter 
Control Z -2.547b -2.201b -2.023b -2.201b -2.023b -2.023b 
Asymp. 
Sig. (2-
tailed) 
0.011 0.028 0.043 0.028 0.043 0.043 
PBM Z -2.981b -2.701b -2.201b -2.803b -2.201b -2.201b 
Asymp. 
Sig. (2-
tailed) 
0.003 0.007 0.028 0.005 0.028 0.028 
a. Wilcoxon Signed Ranks Test 
b. Based on positive ranks. 
 
Figure 9. Means of Area for the 12 weeks of treatment indicate significant 
changes for both groups respectively. The marginal means of parameters of the 
Week  
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control group were higher (>1500 mm2) than that of the PBM (>500 mm), but 
these were significantly reduced overtime.  
The results show statistically significant reduction (p=0.04 Control group vs 
p=0.03 PBM group) in ulcer areas at week 12 (Table 8).  
Table 8 Statistical significant changes in Ulcer Area. 
Group Week1 
Area – 
Week4 
Area 
Week1 
Area -   
Week8 
Area 
Week1 
Area -  
Week12 
Area 
Week4 
Area – 
Week8 
Area 
Week4 
Area – 
Week12 
Area 
Week8 
Area – 
Week12 
Area 
Control Z -2.547b -2.201b -2.023b -2.201b -2.023b -2.023b 
Asymp. 
Sig. (2-
tailed) 
0.011 0.028 0.043 0.028 0.043 0.043 
PBM Z -3.059b -2.803b -2.201b -2.803b -2.201b -2.201b 
Asymp. 
Sig. (2-
tailed) 
0.002 0.005 0.028 0.005 0.028 0.028 
a. Wilcoxon Signed Ranks Test 
b. Based on positive ranks. 
 
The results in Figure 10 show healing in all the other risk factors that may have 
an impact on wound healing in both groups. The results show that a majority of 
healed ulcers (n=7) are from the PBM group. 
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Figure 10. Ulcer healing in different risk factors indicates majority of ulcers that 
healed (n=7) and improved (n=4) were from the PBM group compared to the 
control group healed (n=2) and improved ulcers (n=1). The mean number of 
healed ulcers was 3.33 for both groups respectively. 
The results were further analysed to reflect findings on healing in male gender 
and duration of DM. Tables 9 present the findings of ulcer healing of ulcers that 
were on male participants. 
Table 9. Ulcer healing in the Male gender. 
Group  Grade after Total 
Healed ulcer 
area 
Grade 1 Grade 2 
Control 
 
Grade 
before 
Grade 
1 
Count 1 3 0 4 
% 33.3% 66.7% 0.0% 100.0% 
Grade 
2 
Count 0 1 1 2 
%  0.0% 50.0% 50.0% 100.0% 
PBM 
 
Grade 
before  
Grade 
1 
Count 4 1 0 5 
%  80% 20.0% 0.0% 100.0% 
Grade 
2 
Count 1 3 0 4 
% 25.0% 75.0% 0.0% 100.0% 
Total Count 6 8 1 15 
%  40.0% 53.33% 6.67% 100.0% 
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The findings in Table 10 shows ulcer healing in the participants living with DM 
for >10 years. 
Table 10. Ulcer healing and Duration of DM (>10year). 
Group  Grade after Total 
Healed ulcer 
area 
Grade 1 Grade 2 
Control 
 
Grade 
before 
Grade 
1 
Count 1 1 0 2 
% 33.3% 66.7% 0.0% 100.0% 
Grade 
2 
Count 0 1 0 1 
%  0.0% 100.0% 0.0% 100.0% 
PBM 
 
Grade 
before  
Grade 
1 
Count 4 1 0 5 
%  80% 20.0% 0.0% 100.0% 
Grade 
2 
Count 2 0 0 2 
% 25.0% 75.0% 0.0% 100.0% 
Total Count 7 3 0 10 
%  70.0% 30.0% 0.0% 100.0% 
 
4.4 The Control group results 
Initially, there were nine ulcers in this group; however, at week seven, one control 
participant left the study. Only eight ulcers stayed in this study for 12 weeks or 
until healed. The following pictures and line graphs present the results from 
Control participant 1 to 9 to show ulcer-healing progress. 
4.4.1 Control 1  
A 52-year-old Indian male participant with a Grade 1 ulcer on the plantar aspect 
of his right. Ulcer of five months duration, a smoker and a person with diabetes 
for five years. The ulcer healed within six weeks (Figure 11.1 and 11.2). 
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Figure 11.1. Control 1 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after healing (Week 6). 
 
Figure 11.2. Control 1 ulcer progress graph shows the ulcer area and parameter 
decreased by ~ 11% and < 1% in six weeks. These measured the site where the 
healed ulcer is/was.  
  
4.4.2 Control 2  
A 59-year-old Caucasian male participant with a Grade 2 ulcer on the lateral 
plantar aspect of his left foot (amputation site). Ulcer duration: 2 months. Was 
also a smoker and living with diabetes for 17 years.  
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Figure 12.1. Control 2 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 12). 
Figure 12.2. Control 2 ulcer progress graph shows the ulcer area increased 
between week 4 and week 5. Also shows how it decreased between week 7 and 
week 11.  
 
4.4.3 Control 3  
A 52-year-old Black African female participant with a Grade 1 ulcer on the lateral 
aspect of her leg. Ulcer of four months duration and a diabetic and hypertensive 
for two years. 
0
100
200
300
400
500
600
1 2 3 4 5 6 7 8 9 10 11 12
m
m
²
Weeks
Control 2 Ulcer 
Area Perim.
41 
 
 
Figure 13.1 Control 3 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 12). 
 
Figure 13.2 Control 3 ulcer progress graph shows ulcer healing in 12 weeks. The 
graph shows decreased by 98.6% by week 12. 
 
 
 
4.4.4 Control 4  
A 56-year-old Caucasian female participant with a Grade 1 ulcer on the plantar-
medial aspect of her left hallux. Ulcer of 2 months duration and had diabetes for 
15 years.   
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Figure 14.1. Control 4 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 6) 
Figure 14.2. Control 4 ulcer progress graph shows how the ulcer area decreased 
by ~ 80% in six weeks. 
 
4.4.5 Control 5 
A 74-year-old Indian male participant who presented with a Grade 1 ulcer on his 
left foot plantar aspect. Ulcer duration: 24 months and diagnosed with diabetes 
27 years ago. 
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Figure 15.1 Control 5 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 8). Participant left the study. 
 
Figure 15.2. Control 5 Ulcer progress graph shows how the ulcer area decreased 
by ~ 63% in eight weeks.
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4.4.6 Control 6 
A 44-year-old Black African male with two Grade 2 ulcers on both feet plantar 
metatarsal area. Ulcer of two-year duration and diagnosed with Diabetes and 
Hypertension eight years ago. 
 
Figure 16.1. Control ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 12). 
 
Figure 16.2. Control 6 Ulcer progress graph shows how the ulcer area decreased 
by ~ 51% in 12 weeks. 
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4.4.7 Control 7 
A 54-year-old Indian male who presented with a Grade 1 interdigital ulcer (post 
digit amputation). Ulcer of three months duration and diagnosed with DM and 
Hypertension for six years. 
 
Figure 17.1 Control 7 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 12). 
 
 
Figure 17.2. Control 7 ulcer progress graph shows how the ulcer area decreased 
by ~ 83% in 12 weeks. 
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4.4.8 Control 8 
A 57-year-old Coloured female who presented with a Grade 1 ulcer on the 5th 
plantar metatarsal aspect of the right foot. Ulcer of 3 months duration and 
diagnosed with DM and Hypertension for eight years. 
 
Figure 18.1 Control 8 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 12). 
 
Figure 18.2. Control 8 ulcer progress graph shows how the ulcer area decreased 
by ~ 58% and healed in 12 weeks. 
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4.4.9 Control 9 
A 65-year-old Caucasian male who presented with a Grade 1 ulcer on the plantar 
metatarsal area of the right foot. Ulcer of six months duration, diagnosed with DM 
ten years ago and a smoker. 
 
Figure 19.1 Control 9 ulcer: shows the ulcer before podiatric intervention (Week 
1) and after podiatric intervention (Week 6). Participant left the study. 
 
 
Figure 19.2. Control 9 ulcer progress graph shows how the ulcer area decreased 
in six weeks before the participant left the study. 
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4.5 Photobiomodulation group results 
Overall, 12 ulcers received irradiation in the treatment group over the 12 weeks, 
and one participant decided to withdraw from the study at week four. This section 
presents visual results from participants 1 to 10 in pictures and line graphs to 
show ulcer-healing progress.  
4.5.1 Participant 1 
A 57-year-old Indian male diagnosed with Diabetes 25 years ago and is a smoker. 
He presented with two Grade 1 ulcers of three-month duration on his below the 
knee amputation site.  
Figure 20.1.  Participant 1 Ulcer 1: shows the ulcer before PBM (Week 1) and 
after PBM (week 8). 
Figure 20.2. Participant 1 Ulcer 1-progress graph shows ulcer healing in eight 
weeks. 
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Figure 20.3. Participant 1 Ulcer 2: shows the ulcer before PBM (Week 1) and 
after PBM (Week 8).  
Figure 20.4 Participant 1 Ulcer 2-progress graph shows ulcer healing in eight 
weeks. 
4.5.2 Participant 2 
A 60-year-old Caucasian female diagnosed with diabetes for six years. She had 
a previous history of amputation of all digits due to non-healing ulcers. Presented 
with a Grade 2 ulcer of 24-month duration on the plantar aspect of her right foot.  
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Figure 21.1. Participant 2 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 12). 
 
Figure 21.2. Participant 2 Ulcer progress graph shows the perimeter was 
constant whereas the area decreased significantly by ~82% in 12 weeks of PBM. 
4.5.3 Participant 3 
A 49-year-old Black African male with a Grade 1 ulcer on the forefoot (post-
amputation site) of seven weeks duration. Diagnosed with Diabetes and 
Hypertension 11 years ago. 
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Figure 22.1. Participant 3 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 9). 
 
 
Figure 22.2. Participant 3 Ulcer progress graph shows ulcer healing in nine 
weeks.  
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4.5.4 Participant 4 
The participant was a 52-year-old Caucasian female diagnosed with diabetes 22 
years ago. She presented with a Grade 1 ulcer of 12-month duration on her left 
plantar aspect of the first metatarsal head.  
Figure 23.1. Participant 4 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 12). 
 
Figure 23.2. Participant 4 Ulcer progress graph shows significant improvement 
of the ulcer in 12 weeks. Ulcer area decreased by ~ 92% and parameter 
decreased by 62%. 
4.5.5 Participant 5 
A 62-year-old Black female participant who presented with a Grade 1 ulcer of 8-
month duration on her right foot plantar aspect of the fifth metatarsal. Diagnosed 
with diabetes 16 years ago. 
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Figure 24.1. Participant 5 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 12). 
 
Figure 24.2. Participant 5 ulcer progress graph shows ulcer healing in 12 weeks. 
4.5.6 Participant 6 
This participant was a 52-year-old Caucasian male who presented with a Grade 
2 ulcer on his left foot on the plantar aspect of his second metatarsal head. Ulcer 
duration: 19 months. The participant is a smoker, diagnosed with diabetes two 
years ago. 
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Figure 25.1. Participant 6 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 12). 
 
Figure 25.2. Participant 6 Ulcer progress graph shows the ulcer did not 
significantly improve in its perimeter and area. Ulcer area decreased by ~ 44% 
and parameter decreased by ~ 28%.  
4.5.7 Participant 7 
A 56-year-old Indian male participant who presented with two ulcers on his right 
foot plantar aspect. Ulcer duration of 3 months and diagnosed with diabetes 16 
years ago. 
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Figure 26.1. Participant 7 ulcers before PBM (Week 1) and after PBM (Week 6). 
 
Figure 26.2. Participant 7 Ulcer 1(Grade 1) progress shows ulcer healed in four 
weeks.  
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Figure 26.3. Participant 7 Ulcer 2 (Grade 2) progress shows ulcer significant 
improvement in six weeks. Ulcer area decreased by ~ 75% and parameter 
decreased by ~ 41%. 
4.5.8 Participant 8 
This participant was a 46-year-old Black female who presented with a Grade 2 
ulcer on her right lateral-dorsum aspect of the fifth toe. Ulcer of one-month 
duration and diagnosed with DM and Hypertension 5 years ago.   
Figure 27.1. Participant 8 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 7). 
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Figure 27.2. Participant 8 Ulcer progress graph shows ulcer healing in seven 
weeks. 
4.5.9 Participant 9  
A 44-year-old Black African male diagnosed with Diabetes and Hypertension 
eight years ago. Who presented with two Grade 2 ulcers on both feet plantar 
metatarsal area. Ulcer of two years duration. The ulcer on the left foot was on the 
PBM treatment as participant 9, and the right foot was control 6. 
 
Figure 28.1 Participant 9 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 12). 
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Figure 28.2. Participant 9 Ulcer progress graph shows the ulcer significantly 
improve in 12 weeks. Ulcer area decreased by ~ 93% and parameter decreased 
by ~ 73%. 
 
4.5.10 Participant 10 
A 44-year-old Coloured male who presented with a Grade 1 ulcer on the plantar 
metatarsal area of the right foot. He smokes and presented with an ulcer of two 
months duration and a diabetic for three years. 
 
Figure 29.1 Participant 10 ulcer: shows the ulcer before PBM (Week 1) and after 
PBM (Week 12). 
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Figure 29.2. Participant 10 Ulcer progress graph shows the ulcer healed in 12 
weeks. 
4.6 The Pain Intensity Assessment results 
In this study, each participant had to complete a pain intensity assessment 
(Appendix G) after each Low-Level Laser irradiation session. Tables 11-15 
present the reported changes in pain, heat, erythema, pricking and itching/tingling 
sensations; experienced during irradiation/treatment between week one and 
week 12. 
The results in Table 11 shows that by week 12, 100% of the participants did not 
experience pain. 
Table 11 Pain scale in Week 1 and 12. 
Group  Week12 Pain Scale 
None 
Week 1 Pain Scale None Count 7 
% 58.3% 
Mild Count 4 
% 33.3% 
Moderate Count 1 
% 8.3% 
Total Count 12 
 
100.0% 
0
20
40
60
80
100
120
140
160
180
1 2 3 4 5 6 7 8 9 10 11 12
m
m
²
Weeks
Participant 10 Ulcer
Area Perim.
60 
 
The results in Table 12 show that 90% of the participants did not experience heat 
by week 12 and only 10% experienced mild heat. 
Table 12 Heat scale in Week 1 and Week 12. 
 
The results in Table 13 show that 70% of the participants did not observe 
erythema by week 12 of the study. 
Table 13 Erythema scale in Week 1 and Week 12. 
 
 
 
Group  Week12 Heat Scale  
None Mild  Total  
Week 1 
Heat 
Scale 
None Count 6 0 6 
% 100.0% 0.0% 100.0% 
Mild Count 1 1 2 
% 50.0% 50.0% 100.0% 
Moderate Count 2 0 2 
% 100.0% 0.0% 100.0% 
Total Count 9 1 10 
 
90.0% 10.0% 100.0% 
Group  Week12 Heat Scale 
None Mild  Moderate  Total  
Week 1 
Erythema 
Scale 
None Count 6 0 2 8 
% 75.0% 0.0% 25.0% 100.0% 
Mild Count 1 0 0 1 
% 100.0% 0.0% 0.0% 100.0% 
Moderate Count 0 1 0 1 
% 0.0% 100.0% 0.0% 100.0% 
Total Count 7 1 2 10 
 
70.0% 10.0% 20.0% 100.0% 
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The results in Table 14 show that only 10% of participants still experienced mild 
to moderate pricking sensation at the end of this study where 80% did not. 
Table 14 Pricking sensation scale in week 1 and 12. 
 
The results in Table 15 show that only 10% of participants still experienced 
itching at the end of the study whereas 90% did not. 
Table 15 Itching/Tingling sensation scale in week 1 and 12.  
Group  Week12 Pricking Scale 
None Mild  Moderate  Total  
Week 1 
Pricking 
Scale 
None Count 5 0 0 5 
% 100.0% 0.0% 0.0% 100.0% 
Mild Count 3 1 1 5 
% 60.0% 20.0% 20.0% 100.0% 
% 0.0% 100.0% 0.0% 100.0% 
Total Count 8 1 1 10 
 
80.0% 10.0% 10.0% 100.0% 
Group  Week12 Itching/Tingling Scale 
None Mild  Total  
Week 1 
Itching/Tingling 
Scale 
None Count 6 0 6 
% 100.0% 0.0% 100.0% 
Mild Count 3 1 4 
% 75.0% 25.0% 100.0% 
Total Count 9 1 10 
% 90.0% 10.0% 100.0% 
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CHAPTER 5: DISCUSSION 
5.1 Introduction 
Non-healing wound is a wound that does not improve after four weeks of standard 
treatment and supportive measures on time, and these commonly include 
diabetic foot ulcers (Frykberg and Banks, 2015). Diabetes increases the risk of 
developing a wide range of foot complications, including foot ulceration. Foot 
ulceration always precedes major leg amputations, and evidence suggests that 
a lower leg is lost every 30 seconds due to diabetes somewhere in the world (IDF, 
2015). Diabetes-related amputations have a dramatic effect on the quality of life 
and life expectancy and are a substantial financial burden on the health care 
system (Rheeder, 2006; Brem and Tomic-Canic, 2007).  
Thus, there is an urgent need to look at all available treatment interventions in 
the management of diabetic foot ulcers (DFUs). Such an approach is more 
suitable for low-resources countries like South Africa (RSA), which should include 
instigating technology intervention such as PBM. People with diabetes can ill 
afford chronic DFUs that takes a long time to heal, arguably in the I.R 4.0 era; 
technological advancements should begin to influence patient care. To date, 
ulcers treated using conventional podiatric interventions have been shown to take 
too long to heal. Low-level laser therapy is a growing technology that is gaining 
evidence for efficacy in a variety of specialities. Despite some scepticism, PBM 
has achieved reliable status in wound healing, skin rejuvenation, pain 
attenuation, and allergy-related conditions. Recent studies support its 
effectiveness in various areas such as wound healing, skin rejuvenation, and pain 
alleviation (Kim & Calderhead, 2011). However, in RSA, the efficacy of PBM in 
the treatment of chronic wounds remains unknown and in fact, under-researched.  
In this study, for the first time, DFUs in diabetic patients were treated with PBM 
and found evidence of its effectiveness in reducing wound healing time. 
The preliminary findings of this study, which aimed to assess the potential efficacy 
of the PBM system used in DFUs treatment are encouraging. However, the 
researcher would like to acknowledge the small treatment patient population as 
a limitation. However, as alluded to in chapter three, an experimental design 
study aims to show that two variables are statistically related. That is to show that 
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the independent variable caused the observed changes in the dependent 
variable. The researcher and supervisor feel that despite the limited participant 
numbers, the findings of the study shows that PBM irradiation led to reduced 
wound healing times. Thus, despite the limited study participants, the range of 
wound types and stages provides insightful findings on the efficacy of PBM when 
compared with podiatric interventions. 
The researcher recruited participants from SOPD due to the nature and holistic 
treatment of DFUs. Only a few patients were willing to participate, as they were 
not familiar with PBM and their clinicians were uncomfortable with them having 
this unknown intervention. The scepticism by both treating clinicians could help 
explain the low number of participants despite the large population of patients 
with diabetes seen at hospitals.  
In South Africa, there is limited data on the overall treatment of, and the healing 
time of DFUs. The use of phototherapy in vitro has shown significant 
improvement in DFU cell. Until this study, there has been limited evidence on the 
effectiveness of phototherapy in treating diabetic foot ulcers in vivo.  
This preliminary study used PBM irradiation on chronic diabetic lower limb ulcers 
in Type II Diabetic patient with Fitzpatrick skin type III and V. The findings have 
shown a good response of DFUs healing time to a combined treatment of 
podiatric intervention and PBM.   
5.2 Role of podiatrists in DFUs management. 
Podiatrists have become the point persons on the wound management team, 
often the first to recognise the presence of or the impending formation of a limb- 
and life-threatening wound. A typical lower extremity examination with a podiatric 
focus considers the patient from four essential viewpoints: vascular, 
dermatologic, orthopaedic, and neurologic. Assessment that includes these four 
points is essential to treat a lower extremity wound properly.  
However, in RSA, despite podiatrists inclusion amongst the healthcare 
professionals that deal with or manage DFUs ulcers, their clinical interventions 
remain ill-defined. Thus, nurses and surgeons manage the majority of DFUs 
either in a vascular outpatient department or the surgical outpatient department 
(SOPD). There is a limited number of 45 podiatrists in RSA employed in the 
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Gauteng Department of Health (GDoH) (Bodenstein, 2018). Thus only a few 
clinicians (doctors and nurses) refer to these healthcare professionals due to their 
limited availability and poor understanding of what they do. 
Podiatrists play an essential role in the multidisciplinary team in DFUs 
management.  They use treatment which includes both conservative and surgical 
modalities. Understanding the biomechanics of the lower extremity is principally 
emphasised in the education and training of a podiatrist. Understanding 
biomechanics is particularly crucial in the context of the diabetic foot where 
structural and subsequent biomechanical abnormalities often 
precede ulcer development. Preventive ulcer development strategies employed 
by a podiatrist include regular monitoring, routine care of calluses, and orthoses 
or shoe recommendations. Further, podiatrists use simple interventions like 
regular callus debridement to prevent increases in focal pressures in order to 
reduce the likelihood of ulcer formation. However, there continues to be a poor 
understanding of the podiatrists' role in the management of DFUs in RSA. 
The lack of awareness about the Podiatry service and Diabetic foot specialist 
seems to be a problem not only in RSA but also in other low-middle-income 
countries such as Nigeria and Ethiopia. According to Edo et al. (2013), there is a 
shortage of trained Diabetic foot specialist in Nigeria, and an incomplete 
multidisciplinary team manages DFUs. According to Mishra et al. (2017), 
podiatrists understands the importance of foot care education, as it controls the 
risk factors of developing foot problems in patients with diabetes. Therefore the 
exclusion of podiatrist in the multidisciplinary team for diabetic foot care results 
into the absence of adequate health education and emphasis on diabetic foot 
care practised in developing countries. If this continues, peripheral neuropathy 
and other risk factors will continue to be a significant component in delayed 
wound healing for these patients (Mishra et al., 2017). 
5.3 Mechanism of PBM and its effect on DFUs 
Low-Level Laser Therapy is the application of light to a biologic system to 
promote tissue regeneration, reduce inflammation and relieve pain. Low-Level 
Laser Therapy does not have an ablative or thermal mechanism, unlike other 
medical laser procedures, but rather a photochemical or photobiomodulation 
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effect (Farivar et al, 2014). Photobiomodulation effect is beneficial in diabetic 
patients on accelerating wound healing in chronic diabetic foot ulcer (Enwemeka, 
1988).  Low-Level Laser Therapy is a treatment that uses low-level lasers to 
change cellular function and is a clinically accepted tool in regenerative medicine. 
It has been especially beneficial in dermatology and dentistry to improve healing 
processes and management of functional disorders (Rochkind et al,1989) .  
The skin is the organ with the most exposure to light more than any other organ; 
thus, it responds well to light wavelengths. The mitochondrial chromophores in 
skin cells absorb photons. Consequently, electron transport, adenosine 
triphosphate (ATP) nitric oxide release, blood flow, reactive oxygen species 
increase activating diverse signalling pathways. To achieve sufficient wound or 
tissue healing and tissue repair, sufficient stem cells activation must be achieved 
(Avci et al, 2013) . Current conventional podiatric interventions cannot achieve 
stem cell activation. Thus, interventions like PBM could have a place in the 
treatment of DFUs. 
Several in vivo and in vitro studies have demonstrated the positive effects of PBM 
on tissues (Nteleki and Houreld, 2012). Low-Level Laser Therapy enhances the 
survival of Adipose-derived mesenchymal stem cells (ASCs) and stimulates the 
secretion of growth factors in the wound bed (Kim et al, 2012). Additionally, PBM 
seems to exert biostimulatory effects on various cell types, including osteogenic 
cells, and bone tissue due to its stimulating effects on osteoblast-like cells and 
accelerates the repair process of the bone (Huertas et al, 2014, Stein eta al, 
2005). Other cellular activities such as enhanced alkaline phosphatase activity 
and improved osteocalcin gene expression are other effects observed with the 
use of Low-Level laser therapy (Renno et al, 2010). Low-level laser therapy 
interventions results indicate a higher inflammatory cells recruitment and a better 
tissue organisation at the site of the injury, with the presence of granulation tissue 
and new bone formation (Bottino, (2005) cited by Amid et al, 2014). The noted 
effects of PBM make it one of the ideal addition in the treatment of DFUs. The 
findings of the current study show the ability of PBM to activate wound healing at 
a cellular level and thus achieve the results noted in this study. Low-Level Laser 
Therapy achieves this by providing direct biostimulative light energy to cells, 
which are the main target of low-level laser therapy. Laser energy results in the 
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stimulation of molecules of cells while having no significant increase in tissue 
temperature, as illustrated in Figure 29. 
Figure 30. Photobiomodulation and the biostimulative processes underlying its 
three primary endpoints: Wound healing, Inflammatory response and Pain 
reduction (Kim, W. and Calderhead, 2011). 
 
Despite the evidence on the effects of PBM on different cell lines, without knowing 
its effects on actual DFUs, it is has been challenging to suggest its inclusion in 
DFUs clinical treatment protocol. This study was designed to provide such 
preliminary evidence by trying to provide primary evidence about the effects of 
PBM on DFUs.  
Significantly, there was a high healing rate of 58.3% in the PBM group compared 
to 25.0% in control. Additionally, 42.9% of ulcers healed before completion of the 
study 12 weeks. Thus, indicating the capabilities of PBM to improve wound 
healing in DFUs. The effect of PBM is seen to enhance wound healing when 
compared to standard podiatric interventions. Intentionally, the majority of ulcers 
59.1% received irradiation with blue light (625nm and 850nm). This approach 
enabled the researcher to demonstrate the ability of PBM to treat DFUs and to 
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observe the effects of PBM on more ulcers and could still allow for comparison 
with validated podiatric interventions.  
The specific characteristics of the tissue within the wound bed play an essential 
role in the wound-healing continuum. When wound bed tissue is nonviable or 
deficient, it delays wound healing. Furthermore, it might provide an opportunity 
for infection to develop, prolongs the inflammatory response, mechanically 
obstructs contraction and impedes re-epithelialisation (Dowsett and Hallern, 
2017). Podiatrists use debridement as a process of removing devitalised tissue 
and foreign material from a wound. Ranges of techniques of debridement 
including surgical, sharp, autolytic, enzymatic, and mechanical debridement, are 
available. However, these techniques are dependent on the patient, the wound 
and the expertise of the clinician. Thus, the current podiatric wound management 
techniques might fail to address this critical area of wound healing adequately.  
Wound healing is a complex process requiring highly coordinated biochemical 
processes at the wound site and immune responses needed for restoring tissue 
integrity. Along with these complex processes involving cellular players, wound 
healing also requires several coordinated biochemical pathways and reactions 
that lead to collagen synthesis and disposal of damaged tissues (Nair, 2018). 
Thus, a treatment modality that can act at a cellular level must accompany 
podiatry interventions to achieve desired healing times. Current evidence 
suggests that PBM can achieve this and allow podiatric interventions to address 
wound healing at this level. PBM can alter the cellular redox state that induces 
the activation of numerous intracellular signalling pathways and alters the affinity 
of transcription factors concerned with cell proliferation, survival, tissue repair and 
regeneration (Peplow, Chung, Ryan & Baxter, 2011) 
5.4 Ulcer grades and duration 
To predict the outcome DFUs outcomes and appropriate diabetic foot ulcer 
treatment, clinician usually use a transparent descriptive classification system. 
The (i) Wagner and (ii) University of Texas (UT) classification are the two 
classification systems used worldwide. Wagner classification focuses on the 
depth of the wound, presence or absence of osteomyelitis or gangrene and the 
extent of tissue necrosis. On the other hand, UT classification considers not only 
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the depth and penetration of wound but also the presence or absence of infection 
and ischemia (Gul et al, 2006). 
A number of studies have observed healing time of DFUs, although mostly 
focused on the healing of ulcers on the sole (Kirsner et al, 2010). On the contrary, 
the current study evaluated all ulcers regardless of position. The reported rates 
of healing usually defined as the percentage of wounds healed by 12 weeks, 20 
weeks, six months, or 12 months vary widely. However, the majority of the ulcer 
will heal entirely between 20 and 52 weeks (Ince et al, 2007). In their review, Ince 
et al (2007) stated that some studies reported healing by 12 weeks in only 18.3% 
of control subjects, whereas others reported 38% healing by 12 weeks (Ince et 
al, 2007). Meta-analysis of patients receiving standard care in randomised 
controlled trials found that only 31% of DFUs receiving conventional podiatric 
therapy heal within 20 weeks, and only 24% heal within 12 weeks (Kirsner et al, 
2010).  
Therefore, to evaluate the efficacy of any DFUs treatment intervention, it is 
essential to ascertain its ability to reduce the healing times is critical. This study 
demonstrated improved healing times of all DFUs treated using PBM. The 
findings of the study show that PBM has the potential to increase ulcer healing 
times. Thus, this intervention might have a space in the management of DFUs.  
Literature confirms that wound duration, is related to wound healing times and 
that old wounds are less likely to heal (Bosanquet and Harding, 2014). 
Additionally, the severity of the ulcer has a direct influence on its healing time 
(Smith-Strøm et al., 2017). Thus, in the current study, the researcher used the 
Wagner classification system to classify or grade all ulcers and recorded the 
duration of each presenting ulcer. This method allowed the researcher to predict 
how long each ulcer could be expected to take before it healed, as indicated in 
literature that links ulcer duration and severity to healing times. The duration of 
the majority of ulcers 63.63% was between 1 and 5 months for both groups and  
59.1% were Grade 1 in both groups. In the PBM group, the majority 53.8% were 
Grade 2 ulcers. Therefore, the healing times recorded in this study are 
remarkable when one considers both the duration and severity of ulcers treated 
using PBM. 
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In their study, Smith-Strøm et al. (2017), found that patients referred to specialist 
health care by general practitioners ≥ 52 days after ulcer onset had a 58% 
decreased healing rate compared to those referred earlier. They also reported 
that ulcers classified as high severity (grade 2/3) were associated with a 
decreased healing rate when compared to low severity ulcers (grade1). Thus, 
early-targeted treatment and referral are essential in the management of DFUS. 
Currently, there is a limited referral of these patients to podiatry services in RSA 
(Ntuli et al, 2018).  
Concerning the relationship between the healing rate, ulcer grade and duration, 
the findings of the current study are in line with current literature. In the current 
study it was noted that subacute ulcers (superficial grade 1 and of 1-5 month 
duration), healed faster (reduce in size) when compared to chronic ulcers (deep 
grade 2 and of more than five months duration). This study produced an 
interesting finding in that, in the PBM group, even deeper ulcers older than five 
months, which notoriously take longer to heal, showed quicker healing rates 
57.1%. Furthermore, in the PBM group, 42.9% of these ulcers had healed entirely 
before week 12. Therefore, the findings suggest that the inclusion of PBM as a 
treatment modality in DFUs might be of some benefits. The main aim of any 
chronic wound management is to reduce healing times and limit or control any 
infections. The PBM seems to do both of these, as noted in the findings of this 
study. Thus, it may be worth considering PBM as a modality for the management 
of chronic wounds. 
 5.5 Risk factors for DFUs and their impact on healing 
According to literature, the risk factors for DFUs include male gender, diabetes 
duration of more than ten years’, peripheral neuropathy, abnormal foot structure, 
peripheral arterial disease, smoking, previous history of ulcer or amputations, and 
poor glycemic control (Kajagar et al, 2011). There is an association between 
these risk factors and poor healing of diabetic ulcers. Therefore, part of any DFUs 
management strategy should address these factors. Hence, the current study 
recorded presenting risk factors, including comorbidities in all the participants. 
The researcher did this to evaluate the PBM intervention in an authentic 
environment, similar to all other DFUs treatment strategies/ interventions.   
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Concerning male gender as being a risk factor for developing DFUs, the current 
study findings were in line with the literature (Amin and Doupis, 2016). In the 
current study, 68.2% ulcers were on male participants, thus supporting literature 
as already stated. The findings of this study showed the ability of PBM to heal 
ulcers in the male gender effectively who are usually associated with 
longstanding DFUs. In this group, the study found complete healing rate in 80% 
of Grade 1 ulcers and 25% Grade 2 ulcers in the PBM group compared to 33.3% 
Grade 1 and none of the Grade 2 ulcers in the control group. Overall, 40% of 
ulcers healed completely and 26.67% improved from Grade 2 to Grade 1 ulcers 
in both groups. The findings of this study provide preliminary evidence that PBM 
modality is effective in inducing wound healing; however, a larger cohort is 
needed to validate the current findings.  
Another significant risk factor that is associated with DFUs is the duration of 
diabetes. Diabetes Mellitus of more than ten years of duration and peripheral 
neuropathy is associated with DFUs (Shahi et al., 2012; Ahmad et al., 2017). In 
this study, 45.5% of ulcers were on participants who had diabetes duration of >10 
years and 59% in this study were on participants diagnosed with peripheral 
neuropathy. These findings confirm suggestions by literature, which states that 
DFUs occur in the presence of peripheral neuropathy (Bergin et al., 2012). In this 
study, healing was noted in 80% Grade 1 ulcers in the PBM group when 
compared to control.   
Other comorbidities such as smoking and hypertension are also associated with 
delayed wound healing. In 54.5% and 81.8% of ulcers, smoking and hypertension 
respectively were risk factors seen in ulcers, in the current study. In this study, 
however, 75% of ulcers, with hypertension and smoking were healed in both 
groups compared to 60% of ulcers with hypertension alone. These findings differ 
from Musa and Ahmed’s findings in 2012, where 65% of smokers did not have 
ulcer healing versus 35% of nonsmokers. Hypertension, on the other hand, did 
not have an effect on wound healing correlating with the current study (Musa and 
Ahmed, 2012).   
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5.6 PBM and its ability to induce wound healing at a cellular level. 
The PHOTOTHERAPY blue light laser, used in the PBM group in this study has 
bactericidal effects. Several studies have found that, at different wavelengths, the 
blue light laser is bactericidal to different infectious organisms such as methicillin-
resistant Staphylococcus aureus (MRSA), Propionibacterium acne and 
Pseudomonas aeruginosa (Houreld, 2014). Enwemeka et al. (2009) found that 
470-nm light kills Hospital Acquired-MRSA and Community Acquired-MRSA in 
vitro, suggesting that using blue light laser might have a similar effect in human 
cases of cutaneous and subcutaneous MRSA infections. These results were 
already found in a study by Lipovsky et al. (2008), which demonstrated that high-
intensity broad-spectrum polychromatic light with wavelengths in the range of 
400–1000 nm kills bacteria in infected diabetic ulcers.  
Wound infections are among the most common problems in diabetic people, and 
an essential factor that prolongs the inflammation stage of wound healing 
(Ranjbar and Takhtfooladi, 2016). These ulcers produce copious amount of 
exudate if there is an infection as it prolongs the inflammation stage (Speak, 
2014; Kavitha et al., 2014; Ranjbar and Takhtfooladi, 2016). During the first 
consultation and wound assessment of the participants in the current study, no 
signs of severe infection (pus and cellulitis) were present. However, the research 
noted wound weeping of clear and sometimes discoloured (tan and brown) 
exudate that is suggestive of low-grade infection. Significantly, weeping reduced 
dramatically with the use of PBM, suggesting the ability of this modality to deal 
with bacteria in the wound. Moreover, there were no reports of new or secondary 
infections during the study in the PBM group. The current study findings are in 
line with literature with other recent studies and thus, provide initial evidence on 
the efficacy of PBM. 
The current study used a combination of 625nm and 850nm to irradiate the 
diabetic ulcers to promote both healing and reduce (chances of) infection. A study 
by Figurova et al. (2016) found that the combination of red and blue laser 
improved the healing of sutured skin incisions in piglets and observed no wound 
infection in either control or treated piglets.  
72 
 
In the current study, the dressing used was a silver-based dressing. Silver 
dressings are ideal to use in wounds where the infection is possible due to their 
antibacterial qualities (Wall, 2010). However, literature shows the limited result in 
the ability of silver-containing dressings inhibit wound infection in DFUs (Storm-
Versloot et al., 2010). This approach allowed the researcher to investigate the 
blue laser ability in preventing or clearing secondary infection of all the ulcers. Of 
course, more research needs to be conducted to investigate whether 
phototherapy alone can prevent wound infection in chronic DFUs in Podiatry 
alone or combination with silver dressing. If a blue light laser is bactericidal to one 
of the persistent infection strain (MRSA), some suggest that phototherapy can 
also be an alternative to drug treatment (Enwemeka et al., 2009). Using it could 
even help avoid polypharmacy and adverse drug effects in patients with DFUs.  
Healing of chronic DFUs can undergo an extended period without any response 
due to multiple complex cellular pathophysiological mechanisms involved in 
patients with diabetes. These involve factors such as hypoxia, dysfunction in 
fibroblasts and epidermal cells, impaired angiogenesis and neovascularisation, 
high levels of metalloproteases, damage from oxygen radicals and advanced 
glycation end products (Petrova & Edmonds, 2006; Guo & DiPietro, 2010).  The 
current podiatric interventions and other conventional methods do not address all 
these factors as part of DFUs treatment, which might explain the long duration 
currently observed in the treatment of DFUs. 
In this context, the current study findings might provide critical input and variation 
in the management of DFUs. Current podiatric interventions are limited in their 
ability to address or initiate healing at a cellular level. However, the properties of 
PBM shows that the use of phototherapy allows for the clinician to target wound 
healing at a cellular level. PBM, phototherapy or photobiomodulation refers to the 
use of photons at a non-thermal irradiance to alter biological activity. The 
mechanism associated with the cellular photobiostimulation by PBM involves a 
wide range of effects at the molecular, cellular, and tissue levels (Avci, Gupta, 
Sadasivam, Vecchio, Pam, Pam & Hamblin, 2013).  
The underlying biological mechanism behind the effects of PBM is thought to be 
through absorption of red and NIR light by mitochondrial chromophores, in 
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particular, cytochrome c oxidase (CCO) contained in the respiratory chain located 
within the mitochondria, and perhaps also by photoacceptors in the plasma 
membrane of cells (Karu and Kolyakov, 2005). 
Consequently, a cascade of events occurs in the mitochondria, leading to 
biostimulation of various processes (Oron, 2011). It is implicit that this absorption 
of light energy may cause photodissociation of inhibitory nitric oxide from CCO9 
leading to enhancement of enzyme activity, electron transport, mitochondrial 
respiration and adenosine triphosphate (ATP) production (Avci, Gupta, 
Sadasivam, Vecchio, Pam, Pam & Hamblin, 2013) as illustrated in Figure 31. 
Thus, PBM alters the cellular redox state that induces the activation of numerous 
intracellular signalling pathways and alters the affinity of transcription factors 
concerned with cell proliferation, survival, tissue repair and regeneration (Peplow, 
Chung, Ryan & Baxter, 2011). 
Thus, the improvement perceptible in the treatment group in this study is arguably 
due to PBMs’ ability to influence wound healing at a cellular level. The targeting 
of wound healing at a cellular level using PBM is a unique way. It might enable 
podiatrists to enhance wound healing. This technology is entirely contrary to 
current podiatric interventions, which focuses on offloading and necrotic tissue 
debridement.  Admittedly, these methods have stood the test of time and have 
produced excellent results. However, the treatment time on these methods can 
take up to a year (Kirsner, Warriner, Michela, Stasik & Freeman, 2010). 
In vitro studies have shown that phototherapy PBM can positively stimulate 
diabetic ulcer, thus promoting healing and wound closure. The ability of PBM 
induce this action is due to its ability to act on fibroblasts resulting in increased 
viability, proliferation, ATP, growth factors, cytokines and nitric oxide as well as a 
decrease in cellular damage and proinflammatory cytokines (Houreld & 
Abrahamse, 2010; Beckmann et al., 2014; Houreld, 2014).  
The findings of this study have shown that PBM can produce similar results in 
vivo as those produced mostly in vitro studies to date in RSA. The findings should 
be well-thought-out in the context of RSA podiatric diabetic foot management 
strategies, which have remained stagnant, and without any innovation. The 
podiatry and wound care professionals should consider the PBM 
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technique/technology as a methodology that can allow clinicians to initiate 
treatment at the most effective level of wound healing, as illustrated in Figure 31.  
 
Figure 31.  Mechanism of PBM at a cellular level (Avci, Gupta, Sadasivam, 
Vecchio, Pam, Pam & Hamblin, 2013) 
In this study, 58.3% ulcers healed in the PBM group compared to 25.0% in the 
control group. The study results are similar with Minatel et al. (2009) who treated 
chronic diabetic leg ulcers in 23 patients that were unresponsive to other forms 
of treatment, where thirteen ulcers were treated with phototherapy (combined 660 
and 890 nm) twice a week until healed, or for a maximum period of three months. 
In the group of ulcers that were irradiated, 58.3% resolved completely, and 75% 
of the ulcers achieved 90-100% healing by day 90 (Minatel et al., 2009).  
A study by Priyadarshini et al.(2018), conducted over 15 days found that 66.6% 
grade 1 ulcers and 4.4% of grade 2 ulcer healed completely, whereas 96.6% 
grade 2 ulcers improved to grade 1 by day 15 (Lenifa Priyadarshini and Kishore 
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Babu, 2018). To date, no studies have documented the average healing times of 
DFUs in RSA. The current study is the first study (limited as it may have been) to 
provide some idea of DFUs healing times.  
The current study found that 80.0% Grade 1 ulcers and 42.9% Grade 2 ulcers 
entirely healed in the PBM group, whereas 57.1% Grade 2 ulcers improved to 
grade 1 ulcers. Significantly, only 20% of grade 1 ulcer remained as grade 1 ulcer 
in the PBM group compared to 66.7% of grade 1 ulcers in the control group. The 
findings of this study are the first to indicate good improvement in DFUs healing 
times using a combination of PBM with podiatric intervention in the management 
of DFUs. Importantly also, the findings highlight the possible value add that can 
come from using PBM in combination with podiatric interventions. Any DFUs that 
treated successfully within 12 weeks signifies a measurable improvement in the 
patient’s quality of life. Additionally, successful DFUs management means a 
reduction of possible amputations.  
Priyadarshini et al. (2018) study findings are similar to those of Kajagar and Godhi 
(2011). Both studies reported positive results in ulcers irradiated daily over 15 
days. The researcher could not achieve this in the current study and ulcers were 
treated twice a week in this study. Treating ulcers twice a week meant that 
participants had to come to the hospital twice a week, all participants complained 
about this due to financial constraints. Depending on the clinician’s decision, 
participants would have come to the hospital once a week or two weeks for 
podiatric management and between one to four weeks for a wound dressing 
change by nurses. This presented a challenge, as no treating clinicians were 
happy about their patients receiving treatment twice a week. The noticeable 
changes in the ulcer that is healing were what motivated participants in the PBM 
group to continue with the study despite the stated challenges. 
In the current study, participants in the PBM group received treatment twice a 
week as compared to daily treatment, which could have been a reason for 
decreased healing rate of some of the ulcers in this study compared to 
participants of Priyadarshini et al. (2018) and Kajagar (2012). However, the 
current study compares adequately with literature concerning the treatment of 
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chronic ulcers. Literature suggests that chronic wounds should be treated once 
or twice a week considered as the maximum (Samaneh et al., 2015). 
5.7 PBM and skin type reaction 
The skin is the organ exposed to light more than any other organ; thus, it 
responds well to light wavelengths. The mitochondrial chromophores in skin cells 
absorb photons. Consequently, electron transport, adenosine triphosphate (ATP) 
nitric oxide release, blood flow, reactive oxygen species increase activating 
diverse signalling pathways. Stem cells can be activated to increase tissue repair 
and healing (Avci et al, 2013). 
Low Level Laser Therapy (PBM) is an adverse effect on free treatment modality 
in the management of ulcers (Priyadarshini et al. 2018; Kazemi-Khoo, 2006). 
However, early studies in dermatology showed some unwanted side effects 
(thermal effects) such as blistering, transient or permanent depigmentation, 
textural change and scarring (Battle & Hobbs, 2003; Battle & Soden, 2009), 
especially in the dark skin tones: Fitzpatrick skin type IV to VI. Notably, recent 
studies show that PBM appears to have a wide range of applications of use in 
dermatology, especially in indications where stimulation of healing, reduction of 
inflammation, reduction of cell death and skin rejuvenation are required (Avci et 
al, 2013). Thus, PBM is used in inflammatory skin conditions without inducing any 
dermatological adverse effects (Kim et al, 2012; Kim & Calderhead, 2011).  
However, the pathogenesis of sensitive skin remains poorly understood. Recent 
studies suggest that an impaired barrier function of stratum corneum in sensitive 
skin facilitates the penetration of irritants, resulting in marked cutaneous 
responses to otherwise harmless stimuli (Farage, 2009). In the histopathologic 
findings examination, exhibits vasodilation and an inflammatory infiltrate in 
people with sensitive skin (Reilly et al, 2000). 
Therefore, the researcher in this study felt it was essential to investigate the skin 
reactions of participants in this study. This approach, the researcher thought it 
would be essential in developing a protocol for the inclusion of PBM in the 
management of DFUs. No participant in the PBM group reported any skin 
complaint during the treatment period. The findings are noteworthy, as they show 
that PBM can play a significant role in the treatment of DFUs. 
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In the current study, 69.2% of the ulcers were from the participants with skin type 
V compared to 30.8% skin type III, in the PBM group. This group of participants 
experienced mild to moderate heat and only one participant in skin type III 
experienced increased heat during her few sessions of treatment. However, there 
was no blistering or depigmentation observed or reported in this participant. 
These results differ from Joensen et al. (2011), who found that irradiating with a 
200 mW, 810 nm laser-induced three to six times more heat in dark skin than in 
the other skin tone groups.  
Erythema was the only “depigmentation” observed in the current study. Notably, 
this was immediately after treatment and was reported to subside between 10 
and 15 minutes. Erythema seen in the participants was not a side effect but rather 
a sign of increased blood flow to the area due to mild heat from PBM, which 
promotes healing. Studies confirm the ability of PBM to improve skin circulation 
in patients with diabetic microangiopathy, as low-level laser irradiation 
accelerates collateral circulation, and enhance microcirculation, thus promoting 
healing (Kazemi-Khoo, 2006).  
Initially, in the first week of study, participants reported mild discomfort, pricking 
and tingling sensation, but by week 12, no participant (100%) reported pain. 
However, by week 12 mild tingling sensation and pricking sensation was reported 
by 10% of the participants. Notably, these were only reported when asked by the 
researchers and were not considered as an issue by the affected participants. 
The reason for the reduction in pain can be due to PBM mechanism of action. 
Furthermore, reduction of tingling and pricking can be due to PBM ability to 
increase ATP production by mitochondria and increase cellular oxygen 
consumption thus promoting nerve regeneration and increased microcirculation 
to the periphery (Beckmann et al., 2014; Houreld, 2014; Kazemi-Khoo, 2006).  
Significantly, all ulcers that healed completely was on the skin type V participants. 
Therefore, these results suggest that PBM for wound management in dark skin 
tone patients is an adverse thermal effect free treatment that promotes wound 
healing. The study is significant in the RSA context as the majority of the 
population most likely fall in this skin tone group. The findings of the study suggest 
that this skin tone population might respond favourably to PBM interventions.  
78 
 
CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
Diabetic ulcers still prove to be a significant health care problem worldwide.  
Despite optimal wound care, complete wound healing rates are still as low as 
60% after one year (Cavanagh et al., 2005; Smith-Strom et al., 2017). If a wound 
is in the process of healing, it should show signs of healing within four weeks and 
heal entirely in three months. However, chronic DFUs undergo an extended 
period without any response due to multiple complex cellular pathophysiological 
mechanisms involved in patients with diabetes. Such delays are because the 
standard podiatric wound treatments are limited in their ability to address and 
initiate healing at a cellular level. 
Several in vitro and clinical studies suggest PBM (red and blue) to promote wound 
healing and bactericidal or prevent infections in diabetic wounded cells and 
patients. However, before this study, no clinical studies were found in RSA that 
have investigated the use and effects of PBM (blue) to manage DFUs or any 
other ulcers presenting in the lower limb in different skin tones. 
This study showed that treating chronic diabetic foot ulcers in skin type III and V 
with PBM in combination with podiatric interventions is more successful than 
treating these ulcers with podiatric interventions alone. This study also showed 
that there are no significant adverse effects with the use of PBM in the darker 
skin individuals, but complete wound healing. . It is also essential to understand 
that if any DFU treated successfully within 12 weeks signifies a measurable 
improvement in the patient’s quality of life. Additionally, successful DFUs 
management means a reduction of possible amputations for these patients. 
The researcher achieved the main aim and objectives of this study despite the 
challenges concerning participant attrition 
6.1 Study Limitations  
The main limitation of this study was the number of participants. The researcher 
identified two reasons that might have led to low numbers seen.  
i. Study protocol. 
The study protocol required each ulcer on the PBM group to receive 
treatment twice a week. Having treatment, twice a week conflicted with the 
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standard dressing protocol set out at the hospital where the participants 
receive their treatment.  
ii. Dropouts. 
The high dropout rate might have been primarily due to costs, as coming to 
the hospital twice a week proved too costly for most if not all participants.  
The acceptance of PBM in treating DFUs would have led to lower attrition rate by 
patients with diabetes. Thus, the main recommendation in this study would be to 
repeat this study after registering it as a clinical trial. 
6.2 Recommendations for future research 
 The larger sample size is recommended to corroborate the findings of the 
current study further. 
 A study should be done to compare the effectiveness of blue laser therapy 
and a silver-based dressing in the prevention and management of local 
infection in chronic diabetic ulcers. 
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Appendix A: Research design (Flow diagram) 
PARTICIPANTS 
-19 patients (22 ulcers)
-Type II diabetes
- Fitzpatrick Type III and V
-Lower extremity ulcer >4 weeks in stable or worsening condition
-Meet all inclusion criteria
-Draw up full patient history and complete study specific questionnaire
↙     ↓   ↓   ↘ 
GROUP 1 (15 patients) 
Skin Type III Control 
-Placebo laser
-Standard podiatric treatment
GROUP 2  
Skin Type III Experiment 
-Phototherapy (480 nm &
850 nm)
-Standard podiatric
treatment
GROUP 3  
Skin Type V Control 
-Placebo laser
-Standard podiatric
treatment
GROUP 4  
Skin Type V Experiment 
-Phototherapy (480 nm & 850
nm)
-Standard podiatric treatment
     ↓   ↓   ↓ 
TREATMENT 
-Twice a week, until ulcer heals/3 months
-Clean the ulcer – 0.9% physiological saline and dry
-Standard podiatry treatment
-Irradiation – phototherapy with 480nm & 850nm
-Wound setting
-Contact mode
-Placebo irradiation
-Dress ulcer
↓ 
ULCER MEASUREMENTS 
-Visual assessment
-Digital photography at 30 cm distance
-Ulcer area and area of ulcer granulation tissue measured using ImageJ® software
INCLUSION CRITERIA: 
1. Diagnosis of type II diabetes with neuropathic or mixed ulcers.
2. Ulcer located on the lower extremity.
3. Ulcer present for a minimum of 4 weeks during which it has been either stable or worsening.
4. Willingness to participate in the study and commitment to follow-up protocol.
5. Sign a written consent to participate in the study.
EXCLUSION CRITERIA: 
1. Evidence of cellulitis, osteomyelitis or gangrene anywhere in the affected extremity.
2. Presence of any of one or more medical conditions such as renal, hepatic, haematologic,
neurologic, or immune disease, which in the opinion of the co-principal investigator (MACF)
constitutes a confounding variable.
3. Presence of malignant disease (other than basal cell carcinoma) not in remission for more than
5 years.
4. Use of oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents.
5. Known infection with HIV or presence of AIDS.
6. Use of other investigational drug or device within 30 days of recruitment into the study.
7. Other leg ulcers, such as ulcers due to arterial insufficiency, decubiti, or vasculitis.
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Appendix C: REC Approval letter. 
93 
Appendix D: Helen Joseph Hospital Research Committee Approval letter. 
94 
Appendix E: Information and Consent form 
INFORMATION AND CONSENT FORM 
PHOTOTHERAPY AND PODIATRIC INTERVENTION FOR THE 
MANAGEMENT OF CHRONIC LOWER LIMB ULCERATIONS IN PATIENTS 
WITH TYPE II DIABETES MELLITUS AND SKIN TYPE III AND V 
Dear Sir/Madam, 
My name is Nozipho Sithole and I am a Podiatry Postgraduate student at the 
University of Johannesburg. I am busy conducting a research study under the 
supervision of Prof Heidi Abrahamse, as a fulfillment for my M.Tech degree in 
Podiatry. 
I would like to invite the  to participate in this clinical study which is investigating 
the effects of phototherapy in the treatment of non-healing lower limb ulcers in 
patients with Type II Diabetes. Please take a few moments to read the attached 
information and consent form (including the terms and conditions thereof). Please 
inform your podiatrist of you decision whether or not to participate in this research. 
Should you have any questions that I or the clinical supervisor is unable to 
answer, please do not hesitate to ask to forward those particular questions onto 
the Laser Research Centre. A speedy response will be made to such questions. 
We hope that you will be able to assist us in our research efforts with your 
participation in this study. 
Kind regards 
______________ 
Miss Nozipho Sithole 
University of Johannesburg 
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INFORMATION AND CONSENT FORM 
PHOTOTHERAPY AND PODIATRIC INTERVENTION FOR THE 
MANAGEMENT OF CHRONIC LOWER LIMB ULCERATIONS IN PATIENTS 
WITH TYPE II DIABETES MELLITUS AND SKIN TYPE III AND V 
In order to decide whether or not you wish to participate in this study, you should 
know enough about the risks and benefits of phototherapy to make an informed 
decision. This form gives you information about the research. Once you 
understand the process, you will be asked if you wish to participate, if so, you will 
then be asked to sign a form prior to treatment. 
What is Phototherapy? 
Phototherapy, also known as Low-Level Laser Therapy and photobiostimulation, 
is a form of light therapy that involves the application of low power laser light to 
injuries and lesions in order to stimulate healing. The exact mechanism of PBM 
is not completely understood. However, it is known that the laser light is absorbed 
by photoacceptor molecules, or chromophores, inside the cells. The effects are 
known to be chemical not thermal. This absorbed energy then stimulate cellular 
metabolism. PBM has been found to stimulate blood flow and in doing so improve 
wound healing and reduce pain as well as inflammation. It has also been shown 
to stimulate the immune system. Many studies have shown that PBM improves 
healing of slow-to-heal/non-healing diabetic ulcers. 
There are no known side effects associated with PBM. Although no pain 
associated with laser irradiation is expected, a light tingling sensation may be felt. 
To help assess this, a short pain questionnaire will be completed after each visit. 
Phototherapy has shown to improve the healing of diabetic ulcers. We hope that 
the information gained from the research studies will increase our knowledge of 
human health and disease, and that this information will lead to better treatments. 
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Economic consideration 
You will not receive any payments for participating in this study. The information 
we will get from participation may help to develop new products and treatments 
and promote the use of phototherapy. 
Treatment Regime 
If you meet the criteria and decide to participate in the study, you will need to 
complete a questionnaire. You will then be treated with low-level laser light twice 
a week until the ulcer heals, or for a maximum of period 3 months (90 days). 
Time to complete such a treatment will depend on the size of the ulcer, the ulcer 
as well as the number of ulcers to treat. The ulcer will first be cleaned with 
physiological saline and allowed to dry. The laser light will then be applied to the 
ulcer and the surrounding area. Following phototherapy, the ulcer will then be 
dressed and covered. At each treatment the ulcer will be visually inspected and 
a digital photograph of the ulcer will be taken. A short pain intensity assessment 
will also need to be completed. 
Participants will be randomly assigned to one of four groups based on the skin 
colour (white and dark brown). Each group will receive a standard podiatric 
treatment for diabetic ulcers; the difference comes with the phototherapy. Two 
groups will be receiving placebo irradiation of the ulcer/s and the other two will 
receive irradiation of the ulcer/s. 
Confidentiality 
All identifiable information that is obtained in connection with your participation 
will remain confidential. When the result of the research are published or 
discussed in conferences, no personal information will be included. By agreeing 
to participate, you give permission for the researcher to use any findings/results 
emanating from the study in research publications/reports and conference 
presentations. You also have a right to refuse to participate. 
Voluntary Participation and Withdrawal  
You are free to choose not to participate in the study, however if you do 
participate you are free to withdraw from the study at any time. If you choose 
not to participate it will not harm your relationship with your podiatrist. 
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Access to information or results of the study 
Results of the study will be made available to participants on request; however 
no names or personal information will be included. 
Questions 
We have used some technical terms in this form, so please feel free to ask about 
anything you don’t understand and consider participation and consent carefully 
before you make a decision. 
Authorization 
I have read (or someone has read to me) the Information and Consent Form and 
have decided to participate in this clinical study being conducted at the Podiatry 
Clinic in conjunction with the Laser Research Centre at the University of 
Johannesburg. Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction. By 
signing below, I give permission for the described treatment and disclosures of 
information. My signature also indicates that I have received a copy of the 
consent/ authorization form. I do not give up any of my legal rights by signing this 
form. 
TICK ONE: 
_____ I wish to participate in this study. 
_____ I do not wish to participate in this study. 
_____________________________ ______________  
Signature of subject  Date 
_______________________________________ 
Print name of subject 
_________________________________ _________________ 
Signature of Person Obtaining Consent  Date 
_______________________________  _________________ 
Signature of Researcher  Date 
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Important contact details: 
Researcher: Miss Nozipho Sithole:   
Clinic Supervisor: Miss Meesha Purbhoo: 011 559 6442 
Study Supervisor: Prof Heidi Abrahamse: 011 559 6550 
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Appendix F:  Questionnaire  
QUESTIONNAIRE 
PHOTOTHERAPY AND PODIATRIC INTERVENTION FOR THE 
MANAGEMENT OF CHRONIC LOWER LIMB ULCERATIONS IN PATIENTS 
WITH TYPE II DIABETES MELLITUS AND SKIN TYPE III AND V 
Personal Details: 
Name and Surname: __________________________File no.: ___________ 
Date of birth (YY/MM/DD): ___________________ Age: ______ 
Gender (please tick one): Male____ Female_____ 
Race (please tick one): Black___White____Coloured____Indian____ 
Asian___ 
Clinical Details: 
1. Have you been diagnosed with type II diabetes (please tick one)?
Yes ___ No___
2. How many years have you been diagnosed with type II diabetes?
3. Are you on any treatment for your diabetes? Yes___ No___
4. If you answered yes to question 3, what treatment are you on?
__________________________________________________________
5. How many weeks/months has the lower limb ulcer/s been
present?________
6. Do you have known infection with HIV (please tick one)? Yes___ No___
7. Do you or have you had a malignant disease? Yes___ No___
8. If you answered yes to question 7, are you in remission? Yes___ No___
9. If you answered yes to question 8, how long have you been in
remission?________________________________________________
10. Are you using any corticosteroids, immunosuppressive or cytotoxic
agents/drugs? Yes___ No___ If yes please specify: ___________
11. Do you have any of the following illnesses/diseases (please tick the boxes
that apply):
Renal          Hepatic           Hematologic
Neurologic (not related to diabetes)  Immune (not related to diabetes) 
Please specify the nature of the disease: 
__________________________________________________________ 
12. Have you been using other investigational drug or device within the last 30
days? Yes___ No___
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Appendix G: Pain Intensity Assessment 
PAIN INTENSITY ASSESSMENT 
PHOTOTHERAPY AND PODIATRIC INTERVENTION FOR THE 
MANAGEMENT OF CHRONIC LOWER LIMB ULCERATIONS IN PATIENTS 
WITH TYPE II DIABETES MELLITUS AND SKIN TYPE III AND V 
Name and Surname: __________________________________________ 
File no.: ___________ 
Date: ______________ 
Instructions: Please circle the one that best describes what you experienced 
during or after phototherapy. 
Pain  
Mild        Moderate   Severe  None 
Heat  
Mild         Moderate   Severe  None 
Erythema (redness) 
Mild         Moderate   Severe   None 
Pricking 
Mild         Moderate   Severe   None 
Itching/Tingling sensation 
Mild         Moderate   Severe   None 
If you experienced any discomfort after the treatment, state the discomfort 
i.e. burning or hot sensation, swelling or other signs that you have
experienced: ____________________________________________________
_______________________________________________________________ 
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Appendix H: Turnitin Report 
